Health | Business Upturn

What are Some of Best Health Insurance Plans for Family in 2026?

News Desk — Wed, 29 Apr 2026 08:59:59 +0000

A sudden hospital visit, a planned procedure, or even routine care can affect your finances if you are not prepared. This is why many households today are actively exploring the best health insurance plans that can support the entire family under one cover.

With several options available in 2026, choosing the right policy is less about picking the cheapest plan and more about finding one that fits your family’s needs. If you are comparing health insurance plans for family, understanding what actually matters can help you make a more practical decision.

What makes a good family health insurance plan?

Not all policies offer the same level of support. While features may look similar, the actual value of a plan depends on how it performs during a medical situation. Here are some factors to consider:

Factors	Description
Sum insured	Should be enough to handle rising medical costs, especially in urban areas
Hospital network	Offers access to cashless treatment across multiple hospitals
Coverage scope	Inclusion of hospitalisation, pre- and post-treatment expenses, and daycare procedures
Waiting periods	Refers to the time before certain illnesses or treatments are covered
Claim process	Look for simple and clear steps for faster settlements

Types of health insurance plans for families

Understanding the structure of available plans can make your search easier.

Family floater plans

These plans cover multiple family members under a single sum insured. They are widely chosen as health insurance plans for family because they offer affordability and ease of management.

Individual plans for each member

Each person has their own coverage. This works well when family members have different health needs or risks.

Some families choose a mix, such as a floater plan for younger members and individual coverage for older parents. This helps balance cost and coverage.

How to choose the right plan in 2026

With healthcare costs continuing to rise, selecting the best health insurance plans requires a practical approach rather than a quick comparison.

Start with your family profile

Consider the number of members, their ages, and any existing medical conditions. A young family may need a different plan compared to one with elderly dependents.

Estimate realistic coverage needs

A low sum insured may reduce premiums, but it may not be enough during a major medical event. Choose a coverage amount that reflects current treatment costs in your city.

Check policy flexibility

Look for options that allow you to increase coverage over time or add members when needed. This is useful as your family grows or your needs change.

Review inclusions and exclusions

Understanding what is covered, and what is not, helps avoid confusion later. This is especially important when comparing health insurance plans for family.

What are some common mistakes to avoid?

While exploring the best health insurance plans, some decisions can lead to gaps in coverage.

Choosing a plan based only on low premium
Ignoring waiting periods for pre-existing conditions
Overlooking sub-limits on room rent or specific treatments
Not reviewing the insurer’s claim support process

Avoiding these mistakes can make a significant difference during actual policy usage.

Conclusion

Healthcare expenses are rising steadily, particularly in metro cities. A well-selected policy does more than cover expenses. It allows you to focus on treatment decisions without worrying about immediate financial pressure. The best health insurance plans are those that remain dependable across different medical situations.

Choosing the right family health insurance plan in 2026 requires a balance between cost, coverage, and long-term usability. There is no single plan that fits everyone. The right option depends on your family’s size, health needs, and financial comfort. Before finalising, take time to compare features that truly matter, not just what looks appealing at first glance.

Technogym celebrates 40th anniversary of Design Icon, UNICA with ART Installation UNICA MENTE

News Desk — Fri, 24 Apr 2026 05:50:24 +0000

Milan, Italy, April 24: Unica, on its 40^th anniversary, has become a timeless icon that defined a new product category: home wellness. Over the years, it has found its place in the world’s most beautiful homes, supported elite athletes, and inspired millions to lead healthier, better lives through its commitment to quality and excellence.

This evolution is expressed through UNICA MENTE, where the product transcends function, occupying a place in culture. An art installation curated by Technogym with art direction by artist Felice Limosani, has been unveiled at Technogym Milano, during Milan Design Week (Salone Del Mobile) 2026.

Unica Mente – 21 to 26 April 2026 at Technogym Milano, Via Durini 1, 20122 Milan, Italy.

Conceived as a moment of cultural reflection, the installation explores the relationship between body, mind, and wellbeing – not as an idea, but as a lived, dynamic connection aligned with Technogym’s purpose of “healthy people, healthy planet.”

Blending real portraits with AI-generated reinterpretations, the work brings together forty personalities including athletes, artists, and cultural icons each deeply connected to a wellness lifestyle. Not mere testimonials, these contributors act as co-authors, offering voices and perspectives that form a collective atlas of meaning. The experience invites visitors into a space of immersion and introspection, prompting reflection on intention, discipline, and awareness.

Extending beyond the installation, each of the forty contributors has selected a school or institution to receive a Technogym Unica; transforming the project into a tangible expression of wellness as a shared, global responsibility.

Long before wellness became a domestic ritual, Unica anticipated the shift; bringing structured, design-led fitness into the home. Today, Homes have become the epicentre of personal wellbeing, a place where fitness is no longer scheduled, but seamlessly integrated into daily life. UNICA MENTE extends this idea beyond the physical product, exploring how wellness at home evolves into a broader cultural and mental framework.

At its core, Unica’s cultural legacy is grounded in performance. Technogym’s iconic home fitness multi-station offers a complete strength and toning workout within the comfort of home, delivering the same quality and safety as the world’s finest gyms.

With over 25 exercises engaging all major muscle groups, from pectorals and shoulders to lats, glutes, deltoids, and biceps it brings comprehensive training into a compact, refined format. Designed and developed by Founder and President Nerio Alessandri, it distils a complete gym into just one and a half square meters. In redefining fitness for the home, Unica continues to shape a vision where wellbeing is not a destination, but a seamless part of everyday living.

Founded in 1983, Technogym is a world-leading brand in fitness, wellness, sport, and health. Technogym provides a complete Ecosystem made of connected smart fitness equipment, digital services, and training content. Thanks to the Mywellness Cloud Platform people can connect to their personal training experience anywhere, both on Technogym equipment and mobile devices. With over 2,500 employees Technogym is present in over 100 countries. More than 85,000 Wellness centers and 400,000 private homes in the world are equipped with Technogym. Technogym has been appointed Official Supplier to the Paris 2024 Olympics for the ninth time, after Sydney 2000, Athens 2004, Turin 2006, Beijing 2008, London 2012, Rio 2016, Pyeongchang 2018 and Tokyo 2020, and it’s the reference brand for the training of worldwide champions.

Website: www.technogym.com

Mediclaim Insurance for Maternity: Coverage, Waiting Period, and Expenses Covered

News Desk — Wed, 22 Apr 2026 08:09:51 +0000

The decision to have children is one of the greatest joys in life. It is a time of excitement and hope and of planning. And the way you plan will affect every aspect of your life, including your financial situation. As you are preparing for this time in your life by taking prenatal vitamins, seeing the doctor, and getting ready for the nursery, there is a very practical question to ask yourself: how are we going to pay for the actual delivery of the baby?

This is where understanding mediclaim insurance for maternity becomes essential. It’s not a separate product you hunt for, but a vital, special-purpose feature within comprehensive health insurance plans for families. Its sole job is to transform the significant, predictable expense of childbirth from a source of stress into a managed part of your family plan.

Let’s be honest; the matter of maternity benefits is much more complicated than most people realize. The key to having a successful experience with your maternity benefits is not necessarily financial savvy; it is understanding what to look for and when to take action. The three pillars of maternity benefits are: what they will cover, how long you will have to wait before you can utilize them, and how they will help you pay for real-life expenses.

What Does Maternity Coverage Actually Cover?

Think of maternity coverage as a dedicated toolkit within your family’s larger mediclaim safety net. A robust toolkit should include:

Medically Required Complications Related to Pregnancy: Because pregnancy is not an exact science, maternity coverage will cover medically necessary hospital inpatient stays that occur during the pre/post delivery period for medically related pregnancy complications such as gestational diabetes and postpartum haemorrhage; therefore ensuring maternity coverage for the complete delivery continuum.

Coverage For A Newborn Baby: While this may seem like a minor portion of maternity coverage, it is the most important part. When your baby is born, he/she automatically qualifies for maternity coverage with most health insurance plans; typically for the first 30 days. That means that during your baby’s first 30 days of life, his/her hospital nursery care, immunizations in the hospital, as well as any time spent in the NICU will be covered by health insurance. The value of this one benefit alone is like gold; it provides peace of mind for families whose children require such care.

Preventive and Routine Care (A Bonus): Some of the more comprehensive health insurance plans for families now offer outpatient department (OPD) benefits that can cover a portion of routine prenatal check-ups, diagnostic scans (like ultrasounds), and postnatal consultations, easing the burden of those frequent, smaller bills.

The Waiting Period: The Rule You Must Plan Around

This is the most important detail, and the one that catches many well-intentioned families off guard. The waiting period is the mandatory time you must hold the policy before you can claim maternity benefits.

The Standard Range: Typically, this period ranges from 9 months to 4 years (48 months). A 9-12 month waiting period is ideal and aligns perfectly with a pregnancy term. A 2–4 year period is common and requires you to think far ahead.

The Non-Negotiable Truth: You must have this coverage in place before you conceive. If you purchase a policy after becoming pregnant, the delivery will not be covered. This makes adding maternity cover a proactive step in family planning. For young couples, adding it early to your health insurance plans for families, even if children are a few years away, is one of the smartest financial decisions you can make.

Breaking Down the Expenses Covered

When reviewing a policy, look beyond the headline “Maternity Benefit” sum (e.g., ₹1,00,000). See how it applies to actual expenses:

Costs for hospital stays are covered as per the total amount insured, but may be limited by room rent sublimits (it is ideal to choose policies with higher or no room rent limits).

The maternity policy should cover the costs of complications, including conditions such as an ectopic pregnancy and pre-eclampsia.

Initial tests and vaccinations provided when the baby is born/completed while at the hospital (such as BCG and Hepatitis B vaccines) should also be covered.

Integrating Maternity into Your Family’s Health Shield

Your mediclaim insurance for maternity shouldn’t be an afterthought; it should be a cornerstone of your family’s overall health strategy.

Choose the Right Base Plan: Start with a robust health insurance plans for families (a family floater) from an insurer known for a high claim settlement ratio.

Add the Rider Early: If it’s not built-in, add the maternity rider as soon as you begin planning for a family. The clock on the waiting period starts ticking the day you add it.

Ensure Adequate Overall Coverage: The maternity sum is a part of your total insured amount. If your total family cover is ₹10 lakhs and you use ₹2 lakhs for delivery, you have ₹8 lakhs left. Ensure that total is sufficient for your family’s other needs.

Conclusion

Choosing the right mediclaim insurance for maternity is a profound act of care for your partner, your future child, and your own peace of mind. It allows you to focus on the miracle of birth, supported by the quiet confidence that comes from knowing you’ve prepared a secure foundation for your family’s newest, and most precious, member.

Lupin launches Dapagliflozin and Metformin Extended-Release Tablets in the U.S. after FDA approval

Aman Shukla — Wed, 22 Apr 2026 04:04:02 +0000

Indian pharma major Lupin Limited has announced the launch of its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States, marking another significant step in its expansion in the anti-diabetic segment.

The newly launched combination drug has received approval from the U.S. Food and Drug Administration (FDA) under the Abbreviated New Drug Application (ANDA) pathway. The product is therapeutically equivalent to Xigduo XR, a widely prescribed medication for managing type 2 diabetes.

Key Product Details

Lupin’s newly approved tablets will be available in multiple strengths, including:

5 mg/500 mg
5 mg/1,000 mg
10 mg/500 mg
10 mg/1,000 mg

These extended-release tablets are designed to help improve glycemic control in adults with type 2 diabetes, aligning with the approved labeling of the reference drug.

Strengthening Lupin’s U.S. Portfolio

The launch reinforces Lupin’s presence in the highly competitive U.S. generics market, particularly in the anti-diabetic therapy segment. By introducing a bioequivalent version of Xigduo XR, the company aims to provide a more affordable treatment option while maintaining the same efficacy and safety standards.

5 Residential Psychiatric Facilities in Bengaluru Specialising in Women’s Mental Health

News Desk — Mon, 20 Apr 2026 11:53:39 +0000

In India, women face different types of mental health issues caused by societal stigma, personal trauma, work-life imbalance, post-partum, etc. Residential psychiatric facilities in Bengaluru offer comprehensive treatment options and exclusive care for women to help them overcome these psychiatric issues.

As per a NIMHANS study from 2019, Indian women are 20% more prone to mental health complications than men (10%). Societal stigma and lack of access to care are two of the reasons that prevent Indian women from seeking help when they experience psychiatric issues.

This is why residential psychiatric centres are here to provide specialised care for women, offering 24/7 medical support and therapy sessions in a controlled environment. Residential settings remove the potential triggers for the patients and allow women to recover.

Key Takeaways:

Indian women are more prone to mental health conditions like depression, anxiety, and other psychiatric issues than men.
Residential psychiatric facilities in Bengaluru offer comprehensive treatment options for female patients who need long-term rehabilitation.
Perinatal depression is one of the leading psychiatric issues among women.

In this blog, we are going to discuss 5 residential psychiatric facilities in Bengaluru that extend support for women experiencing psychiatric disorders.

Which Residential Psychiatric Centres in Bengaluru Are Focused on Supporting Women’s Mental Health?

For those in and around Bengaluru searching for a residential psychiatric centre specialising in women’s mental health, here is a list to take ideas from:

1. Sukoon Health

Sukoon Health offers extensive women-focused care in its inpatient department. The rehabilitation centre has a separate female-only residential wing where patients are given a safe and secure place to overcome their psychiatric issues.

Sukoon Health has a dedicated team of psychiatrists, psychologists, and therapists who evaluate the patient’s mental health status and address issues like:

Psychiatric conditions developed during pregnancy and postpartum (such as psychosis)
Stress and trauma.
Emotional changes, anxiety.

Why It is Good for Women

Experts in Sukoon Health offer women-focused care approaches for its inpatient sections that support women patients to recover from psychiatric issues. Some of these include:

Specialised therapy for women going through reproductive transitions.
Structured treatments for women in the postpartum period.
Developing a women-only Psychiatric ICU (PICU) for rapid crisis intervention.
24/7 care: female nurses and attendants attend to all patients’ needs.

Contact Information

The SukoonHealth Psychiatry Centre

Website: https://sukoonhealth.com/psychiatric-hospital-in-bengaluru/

Contact No: +91 8448156500 / +91 1244265238

Email: admissions@sukoonhealth.com

Address: New BEL Road, 22, 2nd Main Rd,

Poornapura, Bengaluru, Karnataka 560054

Services are also available at facilities in Gurgaon, Chattarpur, and Hyderabad.

2. The Light House Women’s Rehabilitation Care

The Light House Women’s Rehabilitation Care in Bengaluru offers comprehensive and personalised treatment for women struggling with psychiatric issues. The rehabilitation centre offers a dedicated inpatient rehabilitation program with a structured, supportive treatment environment.

At the Light House Women’s Rehabilitation Centre, several types of complicated mental health conditions are addressed. The treatment programs are designed to support individuals in overcoming the following conditions:

Depression
Anxiety Disorders
Schizophrenia
Post-Traumatic Stress Disorder (PTSD)

Why It is Good for Women

Every individual woman’s mental health issues are unique, depending on her condition. Therefore, the treatment options also needed to be unique. It offers:

A targeted treatment plan is developed by considering the circumstances of the female patients.
The treatment plan often includes treating the psychiatric issues with medications.
The residential treatment program of Light House Women’s Rehabilitation also offers comprehensive therapeutic sessions, which include one-on-one therapy, group therapy, and family therapy sessions.

Contact Information

The Light House Women’s Rehabilitation Care’s Website: https://thelighthousebangalore.org/

Contact No: +91-9148792645

Email: thelighthousebangalore@gmail.com

Address: 27, Priyank Villas, Bagalur Main Rd,

Munneshwara Block,

Kattigenahalli, Bengaluru, Karnataka 560063

3. Cadabam’s Adrutha

Cadabam Hospital’s Adrutha is a leading residential rehabilitation centre in Bengaluru, particularly designed with a focus on delivering affordable mental health services. The rehab centre emphasises delivering personalised care for every woman.

The team of experts in Cadabam’s Adrutha includes clinical psychologists, psychiatrists, and medical professionals. These specialists in addressing critical mental health issues like depression, bipolar disorder, Obsessive Compulsive Disorder (OCD), schizophrenia, etc. Cadabam’s Adrutha offers residential programs for female patients who need a long-term recovery.

Why It is Good for Women

Cadabam’s Adrutha is beneficial for women experiencing psychiatric challenges because it offers specialised women-centric care in a safe, judgment-free environment. The expert multidisciplinary team of professionals oversees the treatment and recovery process of the residential patient, offering extensive care.

Adrutha also offers post-rehabilitative care and supporting programs, which help these women to quickly recover from their mental disorders.

Contact Information

Cadabam’s Group’s Adrutha: https://www.cadabams.org/

Contact No: +91 96111 94949 / +91 73532 26622

Email: info@cadabamshospitals.com

Address: Gulakamale Village, Near Kaggalipura,

17th Mile Kanakapura Road, Post Taralu,

Bangalore-560082, Karnataka

4. Maarga Mindcare

Maarga Mindcare psychiatry hospital offers residential care for women experiencing mental health complications. Located in Bengaluru, this rehabilitation centre offers a comprehensive women’s psychiatry recovery.

What makes Maarga Mindcare different from others is its unique pre- and post-natal treatments for a range of perinatal mental health complications. These include postnatal depression, Puerperal psychosis, and adjustment disorder. Therefore, the expert pool of psychologists, psychiatrists, and clinicians at Maarga Mindcare offers specialised women’s programmes.

Why It is Good for Women

Maarga Mindcare offers exclusive perinatal care for the residential women patients, where every therapy is designed with trauma awareness. The experts at Maarga Mindcare also focus on evidence-based treatments such as CBT (Cognitive Behavioural Therapy), DBT (Dialectical Behaviour Therapy), and trauma-focused care that helps in the recovery of women experiencing psychiatric complications.

Contact Information

Maarga Mindcare Website: https://www.maargamindcare.com/

Contact No: +91 7026247474

Email: info@maargamindcare.com

Address: 23/B, Sector A, Yelahanka New Town,

Bangalore, Karnataka 560064

5. Kshema Mind Care

Kshema Mind Care in Bengaluru offers comprehensive residential psychiatric care and rehabilitation for women suffering from psychiatric complications. The specialists of Kshema Mind Care offer multidisciplinary treatment options that combine psychiatric consultations, medication management, and counselling that support the recovery of the patients.

Why It is Good for Women

Kshema Mind Care in Bengaluru offers a comprehensive rehab service in its peaceful and safe atmosphere. They offer women-exclusive counselling sessions and therapies tailored to the individual needs of the affected individuals. Furthermore, they offer specialised treatments that address pervasive mental illness through vocational assistance and activity therapies.

Contact Information

Kshema Mind Care: https://kshemamindcare.in/

Contact No: +91-96630 77573 | +91-96639 49573| +91-96116 73769

Email: kshemapsy@gmail.com

Address: 716, St Thomas Nagar, Opp. BMTC Bus Depot,

Saibaba Temple Road, Chellagatta, Kumbalgudu Post,

Kengeri, Bangalore – 560074

Opt for a Residential Psychiatric Facility for Women to Start Your Recovery Journey!

Finding residential psychiatry facilities in Bengaluru that offer women-focused treatment? Choose reputed psychiatry facilities that offer evidence-based and compassionate recovery options, especially for women, and embark on your recovery journey.

Iran conflict triggers pharma shock: Are common medicines like paracetamol set to get costlier?

Rashmi Pandey — Fri, 17 Apr 2026 15:46:04 +0000

Common medicines, including Paracetamol, may soon become costlier in India, with chemists in Visakhapatnam warning of a potential 30–40% increase in drug prices amid global supply disruptions linked to the ongoing Iran-related geopolitical tensions.

According to inputs from local pharmaceutical traders and chemist associations, rising costs of raw materials and disruptions in international supply chains are beginning to impact the pricing of essential medicines. The situation has been attributed to escalating tensions involving Iran, which is affecting the availability and transportation of key pharmaceutical ingredients.

Industry sources indicate that Active Pharmaceutical Ingredients (APIs), many of which are sourced globally, are witnessing price fluctuations due to increased freight costs, insurance premiums, and logistical uncertainties. These factors are contributing to a broader “pharma cost shock,” which is expected to reflect in retail medicine prices in the coming weeks.

Chemists in Visakhapatnam have cautioned that widely used over-the-counter drugs like paracetamol could be among the first to see price hikes, given their high demand and dependence on stable supply chains. The warning highlights concerns among retailers and distributors regarding stock availability and procurement costs.

The pharmaceutical supply chain is closely tied to global trade routes, and any disruption—particularly in energy corridors and shipping lanes—can have a cascading effect on manufacturing and distribution. Increased transportation costs and delays are already being reported by industry participants.

As of now, there has been no official notification from regulatory authorities regarding price revisions. However, stakeholders within the pharmaceutical sector have indicated that if current conditions persist, a price adjustment may become unavoidable.

The situation continues to be monitored by industry players, with further clarity expected based on developments in global markets and supply chain stability.

Asics Novablast 5 Review: The Most Sensible Running Shoe You Can Buy in India Right Now

Aditya Bhagchandani — Thu, 16 Apr 2026 08:31:54 +0000

There is a certain kind of running shoe that does not ask anything of you. It does not demand a specific gait. It does not punish you for going out on tired legs. It does not make you feel like you need to earn it. The Asics Novablast 5 is that shoe — and in a market flooded with over-engineered, over-priced options, that straightforwardness is worth more than most brands will admit.

The Novablast line has quietly become one of the most respected daily trainers on the planet over the last three generations. Version 5 does not reinvent anything. It refines everything. And right now, in 2026, it sits at the very top of the daily trainer conversation globally — including in India, where its pricing makes it one of the most compelling buys on the shelf.

What Has Changed and Why It Matters

The headline update in the Novablast 5 is the FF Blast+ Max midsole. This is Asics pushing more of their premium foam into what is essentially a mass-market shoe. The result is a noticeably more cushioned, more energetic ride than the Novablast 4 — softer on impact, livelier on toe-off, and significantly more comfortable over distances beyond 15 kilometres where lesser foams start feeling flat and dead.

The broader toe box, which Asics has been gradually widening across this line, is a genuine quality-of-life upgrade for Indian runners whose feet tend to run wider than the narrow lasts that European brands historically favoured. Longer runs no longer carry that slow creep of forefoot compression that plagued earlier Novablast versions.

The upper is breathable engineered mesh — appropriate for Indian heat, though not exceptional. On a Mumbai afternoon in April, your feet will still get warm. That is a category limitation, not a Novablast-specific failure.

Who Should Be Buying This

In India, where the Novablast 5 is priced at approximately ₹14,000 to ₹16,000, this shoe targets a very specific and very large group of runners: people who run four to five days a week, cover a mix of easy and moderate-effort distances, and want one shoe that handles all of it without complaint.

It is an outstanding choice for runners building up to their first full marathon. The cushioning is protective enough for 30-plus kilometre long runs, the energy return keeps you honest on tempo days, and the fit is forgiving enough that feet swelling across long efforts does not become a problem.

It is also, frankly, a strong recommendation for anyone coming off injury who needs a shoe that is not going to ask them to adapt their stride aggressively. The Novablast 5 works with you, not against you.

Where It Does Not Excel

This is not a shoe for speed. On interval sessions or race day, you will feel its weight and its softness working against you slightly. The traction is competent on dry Indian roads but falls short on wet surfaces — Bengaluru and Mumbai runners who train through monsoon season will want a second option for those months.

It is also not a stability shoe. Runners who overpronate significantly will find the Novablast 5 accommodating up to a point, but it offers no meaningful correction. If your physio has been nudging you toward a support shoe, this is not it.

The Honest Verdict

The Novablast 5 is the running shoe equivalent of a well-made, perfectly calibrated instrument. It does not have a single flashy feature. It does not make a statement. What it does is deliver a comfortable, energetic, durable daily training experience — session after session — without drama.

In a world where brands increasingly charge for spectacle, Asics has charged for substance. At Indian market pricing, the Novablast 5 is not just good value. It is one of the smartest purchases a serious recreational runner can make in 2026.

Buy it. Run in it. Thank yourself later.

Best for: Daily training, long runs, marathon prep Terrain: Road Price in India: ₹14,000 – ₹16,000 Drop: 8mm | Weight: ~275g (Men’s UK 9)

Health Insurance Premium Calculator in India: Factors That Affect Your Premium Amount

News Desk — Thu, 16 Apr 2026 05:47:30 +0000

Health insurance costs in India can vary depending on several factors, which sometimes makes it difficult for people to understand how premium amounts are determined. Many policy buyers are unsure why the same type of plan may cost different amounts for different individuals. Because of this, it becomes useful to understand the elements that influence premium calculations.

In this blog, you will learn about the key factors that influence health insurance premium amounts in India.

Type of Policy

Choosing the right cover type is one of the first inputs that may influence the premium. When comparing options for health insurance in India, it helps to check whether the cover is meant for one person or shared among family members, as this can change how the cover is set up.

The quoted amount may also shift if the cover is designed to apply after a chosen deductible. Details such as benefit limits and room category terms may further affect the final premium figure.

Age of the Insured Person

Age affects the premium because the chances of needing medical treatment may increase over time. Many plans follow age bands, so the premium may rise when the insured person enters a higher age group at renewal. At older ages, the insurer may review health details more carefully.

Some plans may also include more cost-sharing conditions for older applicants. Regular renewal helps maintain continuity, but the premium may still change when the age group changes.

Sum Insured (Coverage Amount)

The sum insured affects the premium because it sets the maximum payable amount during the policy period. Higher coverage increases the insurer’s exposure, which can raise the price. The gap between coverage slabs is not always equal, since pricing may reflect claim trends and treatment costs.

It is also important to check whether sub-limits or room category conditions restrict usable cover, as these features can influence pricing. Consistent comparison requires matching cover size and key limits.

Medical History and Existing Conditions

Medical history can affect the premium. If a person already has a health condition, the premium may be higher. In some cases, there may also be a waiting period or certain limits on coverage. Details such as past treatment, surgery, or regular medication can also be considered while deciding the premium. That is why correct health information is important at the time of buying the plan.

Policy Features and Add-Ons

Optional benefits can increase premiums because they expand what the policy may pay for or reduce restrictions. A health insurance premium calculator can help compare how feature choices affect the quote. It is sensible to review the feature wording to confirm any limits or conditions.

Reduced or removed sub-limits, where available
Cover for consumables and non-payable items, if offered
Restoration of the sum insured after a claim, where included
No-claim protection features, if present in the wording
Wider room category eligibility, where payouts are linked to room choice

Lifestyle Habits

Lifestyle habits may influence premium assessments when they are linked to potential health risks and the likelihood of future claims. Tobacco use is often viewed as a higher-risk factor and may affect underwriting terms in certain plans. Weight-related indicators may also be considered when they relate to declared conditions or ongoing medication.

Occupation can sometimes be evaluated if it involves a higher injury risk or sustained stress. Providing accurate information helps insurers conduct fair underwriting and supports smoother claim evaluation later.

City of Residence

The city of residence can influence premium calculations because healthcare costs vary across different locations in India. In cities where hospital treatment and specialist services are generally more expensive, premiums may also be higher for similar coverage. Insurers may also consider regional claim patterns while pricing policies in different locations.

Additionally, the availability of network hospitals and cashless treatment facilities can vary by city, which may affect cost assumptions.

Conclusion

A person’s age, sum insured, medical history, policy features, lifestyle habits, and city of residence decide the health insurance premium. Each of these factors plays a role in the amount shown when a person checks or compares a plan. Understanding them helps in reading premium estimates properly and comparing options in a more informed way. It also makes it easier to choose a suitable cover based on healthcare needs and budget.

SUMEET SSG brings European EMS equipment to Maharashtra’s 108 Ambulance Fleet

Riddhima Jain — Thu, 16 Apr 2026 04:44:56 +0000

Pune-based SUMEET SSG has partnered with Spencer India to equip 1,756 ambulances under Maharashtra’s MEMS 108 project with advanced emergency medical equipment.

The multi-year partnership will cover a phased deployment of globally certified stretchers, evacuation systems, immobilisation devices and rescue equipment across the statewide emergency fleet.

The initiative is part of the MEMS 108 program being executed by Sumeet SSG BVG Maharashtra EMS under a 10-year PPP-DBFOT model to strengthen pre-hospital care and emergency response systems.

“Our partnership with Spencer marks a defining moment for emergency medical services in India. MEMS 108 is not just a fleet; it is a complete life-saving ecosystem,” said Summit Salunke, Chairman, SUMEET SSG.

Mr. Manish Malik, MD, Spencer India added, “The partnership will be implemented over several years, starting with phased deployment in the near future. Full fleet integration is expected to occur in later phases. This initiative will position MEMS 108 as one of the first state-wide Emergency Medical Services (EMS) networks in India to adopt a fully European-standard pre-hospital care ecosystem on a large scale.”

The companies said the rollout will position MEMS 108 among the first state-wide EMS networks in India to adopt a European-standard pre-hospital care ecosystem at scale.

331 children test HIV-positive in Pakistan’s Punjab after BBC probe finds syringes reused at government hospital — doctor who raised alarm speaks out

Aditya Bhagchandani — Wed, 15 Apr 2026 05:10:30 +0000

A BBC undercover investigation has found that 331 children in Pakistan’s Punjab province tested HIV-positive after receiving treatment at a government hospital where syringes were allegedly reused — one of the most severe healthcare-associated HIV outbreaks in the country’s recent history and one that has been met with denial from hospital authorities despite video evidence of the violations.

The outbreak was centred on the Tehsil Headquarters Hospital in Taunsa, where hidden cameras placed for over 32 hours inside the facility captured multiple and repeated violations of basic medical hygiene that infectious disease specialists say are sufficient to transmit HIV from one patient to another.

What the BBC footage showed

The undercover investigation captured staff using the same syringe on multi-dose medicine vials — a practice that, even when a new needle is attached, creates a transmission pathway through the syringe body itself. Dr Altaf Ahmed explained the mechanism precisely: even if a new needle is attached, the syringe body retains the virus and will transfer it to the next patient through the shared component.

The footage documented 66 separate instances of staff including a doctor giving injections without sterile gloves. A nurse was filmed handling medical waste with bare hands. Open medicine vials and used needles were left on countertops. Medical waste was not being disposed of properly. Parents of affected children independently corroborated what the cameras captured, with several reporting they had personally witnessed syringes being reused on multiple patients during their children’s treatment visits.

The human cost

The outbreak first came to light in late 2024 when local doctor Gul Qaisrani noticed an unusual spike in HIV cases among children in the Taunsa area — a pattern that in a population with no other known HIV risk factors immediately suggested a healthcare transmission source. The scale of what followed — 331 children testing positive — represents a catastrophic failure of basic infection control at a facility that parents trusted with their children’s health.

Among the cases is the story of Mohammed Amin, an eight-year-old who died shortly after testing positive for HIV following severe illness. His sister Asma was subsequently also diagnosed with the virus. Their family believes both children contracted HIV through contaminated injections during routine treatment at the government hospital — a conclusion consistent with both the pattern of cases and the practices the BBC footage documented.

The scale of sibling transmission within families, combined with the clustering of cases around the same hospital, creates an epidemiological picture that points clearly to a single institutional source — a pattern that has been seen in previous healthcare-associated HIV outbreaks globally including the notorious Larkana district outbreak in Pakistan’s Sindh province in 2019, where over 900 children were found HIV-positive, similarly linked to syringe reuse.

The hospital’s denial

Hospital authorities have denied any wrongdoing despite the BBC presenting video evidence of the unsafe practices directly to hospital management. Dr Qasim Buzdar, who heads the hospital, questioned the footage’s authenticity, suggesting it might be old, taken before he assumed leadership, or even fabricated. He simultaneously maintained that the hospital is safe for patients and that hygiene and infection control remain a top priority.

The combination of denying the footage’s validity while asserting the hospital’s safety record is a response pattern that public health experts and human rights organisations have consistently criticised in healthcare-associated outbreak investigations — it delays accountability, slows corrective action, and extends the period during which unsafe practices may continue.

The Karachi parallel

The Taunsa outbreak is not an isolated incident within Pakistan’s public health system. A similar case was reported at Kulsoom Bai Valika Government Hospital in Karachi, where a family member of a two-year-old girl also diagnosed with HIV described watching the same syringe being filled and administered to one child before being refilled and given to another. The geographic spread of reported cases — from Taunsa in southern Punjab to Karachi in Sindh — suggests systemic rather than localised failures in infection control standards across Pakistan’s public hospital network.

The public health implications

HIV transmission through syringe reuse in healthcare settings is entirely preventable. Single-use syringes are inexpensive, widely available, and their mandatory use in every patient contact is a foundational principle of infection control that has been established for decades. The BBC’s Taunsa investigation documents not a shortage of syringes or a resource constraint that might explain the violations — it documents a practice of reuse that appears to be embedded in the facility’s routine operations, occurring repeatedly across multiple staff members over the 32-hour filming period.

For the 331 children who have tested positive, the diagnosis is lifelong. HIV is a manageable condition with antiretroviral therapy but it requires sustained medication, ongoing medical monitoring, and carries significant social stigma in Pakistani society that compounds the medical burden for affected families. The children who contracted HIV through healthcare reuse at a facility their parents took them to in trust have had their lives altered through no fault of their own or their families.

Disclaimer: This article is based on BBC investigative reporting. Business Upturn is not responsible for any decisions made based on this article.

Bihar bans private practice for allopathic doctors in state health services

Rashmi Pandey — Sat, 11 Apr 2026 14:25:56 +0000

The Bihar government has agreed to the Health Department’s proposal to ban private practice for doctors, physician‑teachers, and other allopathic‑system medical staff belonging to the state’s main health‑service cadres. The decision covers the Bihar Health Services Cadre, Bihar Medical Education Services Cadre, and Indira Gandhi Institute of Medical Sciences (IGIMS) Medical Services Cadre working under the allopathic system of medicine, according to official circulars and state‑level communications on 11 April 2026. The measure is framed as part of an effort to ensure that publicly funded medical professionals devote their full working hours to government hospitals and teaching institutions rather than splitting time between state duties and private clinics.

Under the new arrangements, physicians and medical teachers in these three cadres will no longer be allowed to conduct paid private consultations, run profit‑oriented clinics, or operate in private hospitals on the same days they are on government duty in the state’s health system. The directive is being treated as an amendment to existing service rules for these cadres, and the Health Department has indicated that violations may be booked under disciplinary and, where applicable, legal provisions. The department has also said that the ban is aimed at bridging the perceived gap between public‑sector availability and the long‑standing practice of senior government doctors running parallel private practices.

The Health Department’s proposal highlights that the move is intended to improve in‑patient availability at government hospitals, reduce absenteeism, and strengthen medical teaching in state institutions by keeping more senior clinical staff in public‑sector roles. It notes that the breadth of the cadres, spanning district hospitals, medical colleges, and the premier IGIMS‑linked services, makes the regulation a wide‑ranging step rather than a narrow, department‑specific order. The department has said that the order will be formally notified through the state’s service rules‑amendment process, and that implementation will be monitored by the Health Secretary‑level machinery in coordination with hospital‑level grievance‑handling mechanisms.

The decision is likely to spark debate among doctors’ associations, which have previously contested similar bans as an infringement of professional rights, and among patient groups, who rely on the same clinicians in both public and private domains. The government has indicated that the policy is not a blanket prohibition on all professional activity but a targeted restriction on private, profit‑driven clinical work that overlaps with state‑service hours.

SUMEET SSG partners Pinnacle Industries for Maharashtra MEMS 108 ambulance fleet

Riddhima Jain — Thu, 09 Apr 2026 05:00:11 +0000

SUMEET SSG has partnered with Pinnacle Industries to design and deliver ambulance body kits for Maharashtra’s MEMS 108 project, aimed at strengthening the state’s emergency medical services.

Under the agreement, Pinnacle Industries will develop 255 Advanced Life Support (ALS), 1,274 Basic Life Support (BLS), and 36 neonatal ambulances. The fleet will be deployed across all 36 districts of Maharashtra.

The project will be implemented by Sumeet SSG BVG Maharashtra EMS, a joint venture between Sumeet Group, BVG India Ltd., and SSG Transporte Sanitario (Spain), under a 10-year PPP-DBFOT model. A total of 1,756 emergency vehicles will be deployed and operated.

“Pinnacle Industries brings unmatched expertise in ambulance fabrication, and their partnership is critical to the success of MEMS 108. Our fleet must be strong, reliable, safe, and clinically optimised. Pinnacle’s proven engineering capability ensures that every ambulance we deploy meets the standards required for world-class emergency response.” said Summit Salunke, Chairman, SUMEET SSG.

“We are proud to partner with SUMEET SSG on a project of this scale and importance. At Pinnacle Industries, our focus has always been on engineering excellence and patient-centric design. Through this initiative, we aim to enhance emergency response capabilities and contribute meaningfully to saving lives.” said Mr. Sachin Deshmukh, Executive Director, Pinnacle Industries Limited.

The initiative aims to improve pre-hospital care and emergency response through integrated systems and advanced medical mobility solutions.

Term and Health Insurance: Why You Need Both

News Desk — Fri, 03 Apr 2026 08:15:43 +0000

Personal finance is often a maze of confusing terms. When you start building a safety net, the first question is usually about protection. You might wonder if you should pick one type of cover and ignore the rest. It’s a common trap.

While both are “insurance,” term and health plans do very different jobs. One provides for your family if you aren’t there; the other keeps a hospital stay from wiping out your bank account. Building a solid future isn’t about choosing between them. It’s about how they work together.

How the Two Types of Protection Differ

Health insurance is for the “here and now.” In India, standard plans mainly cover hospitalisation, surgery, and specific treatments. It acts as a shield for your current savings. While you might still face out-of-pocket costs for things like room-rent limits, a policy ensures one medical emergency doesn’t vanish years of hard work in days.

Term insurance is pure life cover. It pays a lump sum to your nominee if the worst happens during the policy term. It isn’t for your medical bills; it’s for the mortgage, school fees, and daily life. While many look at ULIP plans because they mix investment with cover, a basic term plan is a highly effective way to get a high sum assured at a relatively lower premium.

Why Relying on One Leaves You Exposed

Having just one policy is like wearing a helmet but no seatbelt. If you only have health cover, your family has no income replacement if you pass away. If you only have life cover, a major illness could lead to heavy debt, since term insurance doesn’t pay for hospital stays.

Using both creates a complete safety net:

Handling Different Impacts: Health insurance manages the high cost of medical treatments, while term cover handles the massive financial blow of a lost income.
Protecting Your Investments: You won’t have to pull money from ULIP plans or other long-term savings for a sudden operation if your health policy is active.
Long-term Stability: If you have dependants or a home loan, having both lets you invest with confidence, knowing a health scare won’t derail your family’s goals.

Balancing Your Costs and Coverage

View insurance primarily as a cost of security. While ULIP plans are popular for growing wealth, they serve a different purpose than the “raw” protection of a term policy. Remember that in a ULIP, you bear the investment risk as returns are market-linked.

For many, the best setup is simple: a solid health policy for medical needs and if you have dependents or debts a high-value term insurance policy for life risks. This keeps your protection clean and ensures you aren’t paying for extra features you don’t actually need.

Final Thoughts

Term and health insurance aren’t competitors; they are two parts of the same puzzle. One protects your savings while you recover; the other protects your family’s future when you can’t. Putting both in place gives you the certainty that your financial life won’t collapse when things go wrong. Don’t wait for a crisis to find out you’re only half-covered

Oral weight-loss breakthrough: Foundayo hits market with $25 insured pricing

Rashmi Pandey — Wed, 01 Apr 2026 16:00:19 +0000

Eli Lilly and Company has outlined pricing and distribution details for Foundayo (orforglipron), its newly approved oral GLP‑1 receptor agonist for weight loss, following U.S. Food and Drug Administration approval earlier this week. The company confirmed that the medicine will be available through its direct‑to‑patient platform LillyDirect, with multiple pricing options designed to broaden access for patients across insurance types.

Foundayo is approved for adults with obesity or overweight with weight‑related medical conditions and represents a significant development in the rapidly expanding market for oral weight‑loss therapies. Unlike injectable GLP‑1 medications, Foundayo can be taken once daily without restrictions on food or water timing, offering convenience for patients.

Access and pricing structure

According to company announcements, Foundayo will be made available through LillyDirect, where prescriptions are being accepted immediately and shipping will begin on April 6. Patients and healthcare providers can begin ordering Foundayo through this direct channel before broader pharmacy availability.

Under the pricing plan:

Patients with commercial insurance may pay as little as $25 per month using the Foundayo savings card administered through LillyDirect.
Self‑pay patients without insurance coverage will have access to the medication starting at $149 per month for the lowest dose through LillyDirect.
Qualified Medicare Part D beneficiaries may be eligible to obtain Foundayo at approximately $50 per month beginning July 1, 2026, under certain plan provisions negotiated between the company and Medicare coverage programs.

Clinical and market context

Foundayo’s FDA approval marks a milestone for oral obesity therapies. GLP‑1 receptor agonists have transformed weight‑loss treatment options in recent years, historically dominated by injectable drugs. Foundayo’s convenience and pricing strategy reflect Lilly’s effort to compete in a segment expected to grow substantially as insurers and government programs expand coverage.

The drug is recommended to be taken in conjunction with a reduced‑calorie diet and increased physical activity, and company literature warns that combining Foundayo with other GLP‑1 receptor agonists is not advised, given overlapping mechanisms and potential safety concerns.

Insurance and policy considerations

Access for Medicare Part D beneficiaries is a key development for the market, as cost concerns have historically limited uptake of weight‑loss medications among older adults. Company disclosures indicate that eligible Medicare plans may cover Foundayo under cost‑sharing arrangements, enabling beneficiaries to pay around $50 per month starting mid‑2026, though final plan participation and actual costs may vary across insurers and formularies.

Health policy experts have previously noted that not all Medicare plans may adhere to a strict $50 cap, and actual out‑of‑pocket costs could differ based on plan design and coverage determinations.

Commercial outlook

Foundayo enters a market where pricing strategies play a critical role in patient access and uptake. Direct pricing via LillyDirect aims to reduce barriers for both insured and uninsured patients, positioning Foundayo competitively alongside other GLP‑1 therapies that have launched with similar direct‑to‑consumer initiatives.

Industry analysts anticipate that accessible price points and broader insurance coverage will influence market dynamics and utilization patterns for oral weight‑loss medications, particularly as healthcare providers integrate these treatments into obesity management strategies.

Apollo Hospitals expands air ambulance network to speed up critical care access : 1066 EMS to act as central coordination hub for domestic and global transfers

Riddhima Jain — Tue, 31 Mar 2026 06:00:02 +0000

Apollo Hospitals has announced a structured patient transfer initiative to improve access to critical care through coordinated air ambulance services across India and international markets.

The hospital group has signed MoUs with multiple domestic and international air ambulance operators to streamline patient transfers. The initiative will be coordinated through Apollo’s 1066 Emergency Response Network, which will serve as the central hub for managing requests and logistics.

The partnerships aim to address gaps in emergency transport, particularly in remote and underserved regions, where patient transfers are often fragmented and costly. The model integrates ground ambulance support, airport connectivity and air transfers to enable bed-to-bed movement.

“In critical situations, the ability to reach the right hospital quickly can make a life-saving difference. Through our partnerships with specialised air ambulance providers, we are making it easier for patients and families to access advanced care across cities and across borders, in a more coordinated and transparent manner,” said Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals.

The initiative is expected to support faster and more organised transfers for high-acuity cases requiring tertiary and quaternary care.

A New COVID Variant Called Cicada Has Spread to 23 Countries — Here Is What You Need to Know Without Panicking

Aditi Bhogle — Mon, 30 Mar 2026 10:12:58 +0000

A new Omicron subvariant designated BA.3.2 and nicknamed Cicada has been detected in 23 countries, including across 25 or more US states through wastewater surveillance and clinical samples, and in parts of Europe where it accounts for up to 30 percent of cases in some localised pockets. The variant was first identified in South Africa in November 2024 and has been spreading quietly across regions since then. Health authorities have classified it as a variant under monitoring, which means it is being tracked carefully but has not been elevated to the higher-concern categories of variant of interest or variant of concern.

Here is everything known so far, without the panic and without the dismissal.

What Makes Cicada Different

The most striking feature of BA.3.2 Cicada is its mutation profile. The variant carries 70 to 75 mutations on its spike protein, the part of the virus that antibodies from vaccination and prior infection primarily target. For context, the original Omicron variant that caused global waves in late 2021 carried approximately 30 spike mutations, which was itself considered extraordinary at the time and was the primary reason Omicron achieved such rapid immune escape. Delta, the dominant variant before Omicron, carried approximately 10 spike mutations.

Cicada’s 70 to 75 mutations represent a substantially higher mutation load than any previous variant that has circulated widely. This raises the theoretical possibility of immune escape, meaning the variant could partially evade immunity built up through vaccination or prior infection. However the critical point that experts are emphasising is that a high mutation count does not automatically translate into higher severity or greater danger. Mutations affect transmissibility and immune escape potential, not necessarily the virus’s ability to cause serious disease.

How Widespread Is It

Cicada currently accounts for less than 1 percent of COVID cases in the United States despite being detected in more than 25 states through wastewater monitoring and clinical sampling. Its presence in wastewater across such a wide geographic footprint before it becomes dominant in clinical case counts is consistent with the pattern of early spread that characterised previous variants before they achieved dominance.

In Europe, the picture is more uneven, with some localised areas reporting Cicada accounting for up to 30 percent of cases in specific pockets. This geographic variation suggests the variant is in the early stages of expansion and has not yet achieved the kind of consistent dominance in any major market that would indicate imminent large-scale wave dynamics.

The variant has been detected across 23 countries overall, spanning multiple continents, indicating that travel-related spread has already occurred at a scale that makes containment at borders impractical.

Symptoms and Severity — What Cases Look Like

The most reassuring element of the current Cicada data is that the majority of cases reported so far have been mild to moderate in severity. Symptoms are broadly similar to those of earlier Omicron subvariants, including sore throat, fever, and fatigue. No hospital surge has been reported in any country where the variant has been detected. No evidence of higher mortality or more severe lower respiratory disease compared to recent Omicron subvariants has emerged.

Experts emphasise that existing immunity from vaccination and prior infection, particularly the T-cell immune response which targets parts of the virus beyond the spike protein mutations, is expected to continue providing meaningful protection against severe disease even if Cicada achieves partial immune escape from antibody-based immunity. This is the same mechanism that prevented Omicron from causing the hospitalisation and death rates that Delta produced despite Omicron’s greater transmissibility.

Boosters remain key for high-risk groups including the elderly, immunocompromised individuals, and those with significant underlying health conditions, where the additional antibody response from updated vaccines provides an important additional layer of protection.

India’s Response

India is tracking BA.3.2 through INSACOG, the Indian SARS-CoV-2 Genomics Consortium, which was established to monitor COVID variants through genomic sequencing of clinical samples across the country. INSACOG’s surveillance network provides early warning of new variants establishing themselves in India’s diverse population, and health authorities are monitoring the situation as it evolves. No specific domestic surge attributable to Cicada has been reported in India at the time of writing.

The Bottom Line

Cicada is a highly mutated variant that is spreading across multiple countries and warrants careful monitoring. It is not, based on current evidence, a cause for panic. The combination of its apparent mild to moderate severity profile, the absence of hospital surges, the expected continued protection from T-cell immunity against serious disease, and its current low case share even in countries where it has been detected suggests that Cicada is a variant to watch rather than a variant to fear at this stage.

The situation is evolving. The critical indicators to monitor in the coming weeks are whether Cicada begins to achieve dominant case share in major markets, whether any signal of increased severity emerges from countries with higher current prevalence, and whether hospitalisation or mortality data from those markets shows any deviation from the pattern established by recent Omicron subvariants.

Monitor, track, and stay updated through official health authority communications. Do not panic. Do ensure high-risk individuals in your family are up to date on their COVID boosters. And watch for updates from INSACOG and the WHO as the picture develops.

Science Says Masturbation Has a Real Biological Benefit — And It Is Not What Most People Think

Aditi Bhogle — Thu, 26 Mar 2026 13:27:52 +0000

For most of human history, masturbation has been discussed in moral, psychological, or social terms. It has been condemned, pathologised, normalised, and eventually largely ignored as a subject of serious scientific inquiry. What it has rarely been is examined for its potential biological purpose in maintaining reproductive health.

A new study from the University of Oxford, published on March 25, 2026, changes that. The research, conducted by Rebecca Dean, Irem Sepil, and Krish Sanghvi from Oxford’s Department of Biology, provides the strongest evidence yet that frequent ejaculation including through masturbation serves a genuine and measurable biological function: it protects sperm quality by preventing the deterioration that occurs when sperm are stored in the male reproductive tract for extended periods.

'Male masturbation may have an adaptive benefit: it flushes out damaged, stored sperm.'

New Oxford research suggests that the longer sperm are stored before ejaculation, the lower their quality, with implications for men trying to conceive and IVF treatment.

Find out more ⬇️ pic.twitter.com/E6fDvmRESG

— University of Oxford (@UniofOxford) March 26, 2026

The finding reframes one of the most universally practised human behaviours in entirely biological terms. It is not a moral question, not a psychological one, and not a social one. It is a reproductive maintenance mechanism that evolution may have built into male biology for a specific and measurable purpose.

The Problem With Storing Sperm

To understand why the Oxford finding matters, it helps to understand what happens to sperm when they are not ejaculated. Unlike eggs, which women are born with and which age along with their owner, sperm are produced continuously in men from puberty onwards. New sperm are generated constantly. But they do not immediately leave the body. They are stored in the male reproductive tract, waiting for ejaculation, sometimes for days or weeks.

The Oxford study, which analysed data from 115 published studies involving nearly 55,000 men, found that this waiting period is not neutral. Sperm stored in the male reproductive tract deteriorate in quality over time through two primary mechanisms. Oxidative stress, described by the researchers as a biological form of rust, accumulates in stored sperm and causes structural damage. And energy depletion occurs because sperm cells are unusually active and have a very limited capacity to replenish their fuel reserves. Stored sperm eventually run out of energy, reducing their ability to swim effectively and increasing the probability of DNA damage.

The consequence is that sperm which have been stored for longer periods are measurably less healthy than recently produced sperm, regardless of how many of them are present in the ejaculate.

What Masturbation Actually Does Biologically

Here is where the evolutionary hypothesis becomes compelling. If stored sperm deteriorates, and if the male body lacks effective internal mechanisms to remove or repair damaged stored sperm, what is the biological solution?

The Oxford researchers draw on observations from primate studies showing that frequent ejaculation, including through masturbation, improves ejaculate quality in male primates by reducing the proportion of aged, damaged sperm present in any given ejaculate. Applied to humans, the hypothesis is that frequent ejaculation functions as a biological maintenance system. It clears out the accumulated older, more damaged sperm from the reproductive tract and replaces them with the continuously produced newer sperm that have not yet had the opportunity to deteriorate.

In plain language: ejaculating regularly keeps the sperm supply fresh. Masturbation, in the absence of a sexual partner, performs the same biological maintenance function. It is not simply a source of physical pleasure. It may be, from an evolutionary standpoint, a mechanism that male biology developed to maintain reproductive readiness by ensuring that the sperm available at any given moment are as healthy as possible.

The researchers state explicitly that masturbation may have an adaptive benefit in that it flushes out damaged stored sperm. This is a significant scientific claim. It suggests that a behaviour which has been treated as reproductively irrelevant, because no fertilisation can occur from masturbation alone, may in fact serve a reproductive purpose by maintaining the quality of sperm that would be available for fertilisation in subsequent sexual activity.

The Evidence Across the Animal Kingdom

The Oxford team extended their investigation beyond human data to examine whether sperm deterioration during storage is a universal biological phenomenon. They analysed 56 studies across 30 different animal species including birds, bees, reptiles, and mammals. In every species examined, the same pattern emerged. Sperm quality declined during storage, and longer storage periods were associated with worse reproductive outcomes including lower embryo survival rates.

This cross-species consistency is scientifically important because it suggests that sperm deterioration during storage is not a peculiarity of human physiology but a fundamental biological challenge that male reproductive systems across the animal kingdom face. The fact that the same problem exists across such a diverse range of species suggests that evolutionary pressure to solve it, potentially through behaviours that promote frequent ejaculation, would be similarly widespread.

The study also found that sperm deteriorated more slowly when stored inside females than when stored inside males. In several species, females have evolved specialised organs that produce antioxidants which actively protect stored sperm and extend their functional lifespan. Male reproductive systems lack equivalent protective mechanisms, making the male body a comparatively hostile environment for long-term sperm storage and providing additional biological rationale for the frequent ejaculation that removes aged sperm before they deteriorate further.

What This Means for Male Fertility

The practical fertility implications of the Oxford findings are direct and meaningful. The World Health Organisation currently recommends that men abstain from ejaculation for two to seven days before providing sperm samples for fertility analysis or IVF procedures, on the basis that abstinence increases sperm count. The Oxford research suggests this advice may be counterproductive for men whose fertility concern is sperm quality rather than quantity, because the abstinence period allows stored sperm to age and deteriorate even as their numbers increase.

A recent clinical finding supports this interpretation. Men who ejaculate within 48 hours of providing an IVF sperm sample achieve better treatment outcomes than men who follow the standard two to seven day abstinence recommendation. More sperm did not produce better IVF outcomes. Fresher sperm did.

For men who are not actively pursuing fertility treatment, the implication of the research is that regular ejaculation, however achieved, may contribute to maintaining sperm health over time. This does not guarantee fertility but suggests that the concern sometimes expressed that frequent masturbation depletes or damages sperm is not supported by the current evidence. The opposite appears to be closer to the truth.

The Broader Context of Declining Male Fertility

The Oxford researchers note the particular timeliness of their findings given two converging trends. Sexual activity is declining among younger adults in many countries, reducing the frequency of ejaculation and potentially allowing sperm to age in storage for longer periods. And delayed parenthood means more men are attempting to father children at ages when sperm quality is naturally lower.

The combination of these trends may be contributing to the fertility declines documented across multiple countries. The Oxford finding identifies sperm storage duration as a modifiable factor within this broader picture, one that individuals can directly influence in ways that environmental toxins, genetics, and chronological age do not allow.

The Conversation Science Has Been Avoiding

The Oxford study is significant not only for what it finds but for the conversation it forces science and medicine to have about a subject that has been largely excluded from serious reproductive health research. Masturbation has been studied extensively in psychological and sociological contexts. Its potential biological function in reproductive maintenance has received far less rigorous scientific attention.

The finding that it may serve as an evolutionary mechanism for sperm quality maintenance places it squarely within reproductive biology in a way that demands further research. If frequent ejaculation maintains sperm quality, what are the optimal frequencies for different ages and fertility profiles? How does the benefit interact with other factors affecting male fertility? These are questions that the Oxford study opens rather than closes, and they deserve the serious scientific attention that the subject has historically not received.

For now the headline finding is clear enough. Masturbation has a real biological benefit. It keeps sperm fresh. And that, it turns out, matters more for fertility than anyone fully understood before this study was published.

This article is based on research published on March 25, 2026 by Rebecca Dean, Irem Sepil, and Krish Sanghvi from the University of Oxford’s Department of Biology, published via The Conversation. This article is for informational and educational purposes only and does not constitute medical advice. Readers with fertility or reproductive health concerns are advised to consult a qualified medical professional.

Oxford Study Says Ejaculating More Frequently May Improve Sperm Quality — What the Research Actually Found

Aditi Bhogle — Thu, 26 Mar 2026 13:26:16 +0000

A new study published on March 25, 2026 by researchers at the University of Oxford has found that sperm quality declines significantly during periods of sexual abstinence, and that ejaculating more frequently may actually improve the health of sperm in men. The findings, which analysed data from nearly 55,000 men across 115 published studies, challenge the widely held medical advice that men should abstain from ejaculation for several days before fertility tests or assisted reproduction procedures.

The research was conducted by Rebecca Dean, a Research Fellow in the Department of Biology at Oxford, alongside Irem Sepil, a Lecturer in Evolutionary Biology, and Krish Sanghvi, a PhD Candidate in Biology. The study’s findings have significant implications for fertility treatment, reproductive health advice, and our understanding of how male biology ages differently from female biology.

'Male masturbation may have an adaptive benefit: it flushes out damaged, stored sperm.'

New Oxford research suggests that the longer sperm are stored before ejaculation, the lower their quality, with implications for men trying to conceive and IVF treatment.

Find out more ⬇️ pic.twitter.com/E6fDvmRESG

— University of Oxford (@UniofOxford) March 26, 2026

How Male Sperm Storage Works

To understand why the findings matter, it helps to understand how male reproduction differs from female reproduction. Women are born with most of their lifetime supply of eggs, meaning a woman’s age and the age of her eggs are effectively the same. Male reproduction works differently. Sperm are produced continuously from puberty onwards and can be stored in the male reproductive tract before ejaculation. This means a man’s age is not necessarily the same as the age of his sperm at the time of fertilisation.

The question the Oxford researchers set out to answer was: what happens to sperm while they wait in storage? The answer, their data suggests, is that stored sperm ages and deteriorates in ways that meaningfully affect fertility outcomes.

What the Study Found

Analysing semen data from 115 published studies involving nearly 55,000 men, the researchers found that when men abstained from ejaculation, the health of their sperm dropped significantly across multiple measures. Sperm motility, which is the ability of sperm to swim effectively toward an egg, decreased during abstinence. Sperm viability, meaning the proportion of sperm that are alive and functional, also declined. And perhaps most significantly, sperm DNA became more damaged during periods of storage.

The researchers identified two primary biological mechanisms driving this deterioration. The first is oxidative stress, described in the study as a form of biological rust that accumulates in stored sperm and causes physical damage over time. The second is energy depletion. Unlike most cells in the human body, sperm are highly active cells that have only a limited capacity to replenish their energy reserves. When stored for extended periods without ejaculation, sperm essentially run out of the fuel they need to function properly.

The Challenge to Standard Medical Advice

The findings directly challenge guidance from the World Health Organisation, which currently advises against ejaculating for two to seven days before providing a sperm sample for analysis, fertility treatments, or procedures such as IVF. The rationale behind this recommendation has been that abstinence increases sperm count and therefore improves the chances of successful fertilisation.

The Oxford study suggests that while abstinence does increase sperm count, the quality of those sperm may actually be lower than freshly produced sperm due to the deterioration that occurs during storage. The researchers note that their findings support a recent clinical discovery that ejaculating within 48 hours of providing a sperm sample for IVF improves treatment outcomes compared to longer durations of abstinence. In other words, for IVF success, sperm freshness may matter more than sperm quantity.

The Evolutionary Biology Angle

The study also provides an evolutionary perspective on male masturbation that has rarely been explored in mainstream research. The researchers note that in primates, frequent ejaculation from masturbation has been observed to improve the quality of ejaculates. Combined with their findings in humans, this leads the researchers to propose that male masturbation may have an adaptive biological benefit: it flushes out damaged, aged sperm from the reproductive tract and replaces them with fresher, higher-quality sperm.

This hypothesis suggests that what has often been dismissed as having no reproductive function may in fact serve a meaningful biological purpose in maintaining sperm quality across periods when conception is not actively being attempted.

The Pattern Extends Across the Animal Kingdom

To test whether sperm deterioration during storage is a widespread biological phenomenon rather than specific to humans, the Oxford team examined data from 56 studies across 30 different animal species including birds, bees, reptiles, and other mammals. The pattern held consistently across species. In every group examined, sperm quality declined during storage periods.

The researchers found that fathers who stored sperm for longer before ejaculation, and mothers in species where females store sperm internally before fertilisation, produced embryos with lower chances of survival. This suggests the consequences of sperm deterioration extend beyond the sperm itself to affect embryo development and survival.

One particularly interesting finding was that sperm deteriorated at a slower rate when stored inside females than when stored inside males. The researchers suggest this is because females in several species have evolved specialised organs that secrete antioxidants which nourish and protect stored sperm, effectively extending their functional lifespan. This biological asymmetry points to an evolutionary adaptation in which female reproductive systems have developed mechanisms to preserve sperm quality that male reproductive systems have not independently developed.

What This Means for Men Trying to Conceive

The practical implications of the Oxford study are meaningful for couples attempting to conceive, particularly those undergoing fertility treatment. The researchers conclude that using freshly ejaculated sperm for fertilisation could provide a meaningful boost to fertility outcomes by improving sperm quality at the time of attempted conception.

For men undergoing IVF or other assisted reproduction procedures, discussing the timing of ejaculation before sample provision with their fertility specialist in light of these findings is a conversation worth having. The standard two to seven day abstinence window recommended by the WHO may warrant reconsideration in the context of this new evidence, though any changes to clinical protocols would need to be made in consultation with medical professionals on a case-by-case basis.

The Broader Context of Declining Fertility

The Oxford researchers note that their findings are particularly timely given two converging global trends. Sexual activity appears to be declining, especially among young people. And the global trend toward delayed parenthood means that more couples are attempting to conceive at older ages when both egg and sperm quality are naturally lower. The combination of these trends may compound global fertility declines in ways that are only beginning to be understood.

The finding that the duration of sperm storage is a modifiable factor in sperm quality is significant precisely because so many other contributors to fertility decline, including environmental toxins, chronic stress, and genetic factors, are outside an individual’s control. Sperm storage duration, by contrast, is something that can be actively managed, making it one of the few fertility variables that is directly actionable.

This article is based on research published on March 25, 2026 by Rebecca Dean, Irem Sepil, and Krish Sanghvi from the University of Oxford’s Department of Biology, published via The Conversation under Creative Commons licence. This article is for informational purposes only and does not constitute medical advice. Readers with fertility concerns are advised to consult a qualified medical professional.

The Importance of Network Hospitals Near You When Choosing Senior Citizen Policies

News Desk — Fri, 20 Mar 2026 07:21:46 +0000

A senior citizen policy is often judged by premium, cover amount, and waiting periods, but one factor can shape the treatment experience more directly: access to network hospitals close to home. For older adults, distance, admission speed, and claim convenience can influence care at stressful moments.

This blog explains why the best health insurance policy for senior citizens should be assessed not only by cover features, but also by the strength and location of its network hospitals.

Why Nearby Network Hospitals Matter for Senior Citizens

Senior citizens may need regular consultations, tests, planned procedures, or urgent admission. That makes a nearby network hospital far more than a convenience. It can make treatment more accessible, reduce reliance on rushed travel arrangements, and support follow-up care after discharge.

When comparing cover for older adults, the hospital network should be reviewed as carefully as premium, co-payment clauses, waiting periods, and room eligibility. This remains relevant even when decisions are weighed alongside broader family medical insurance needs in the household.

Network Hospitals Enable the Cashless Treatment Facility

The value of network hospitals is closely linked to the cashless treatment facility. At a listed hospital, treatment may be processed through the insurer’s approved system instead of requiring full payment up front and later reimbursement.

For senior citizens, this can reduce immediate financial pressure at admission and lessen paperwork for family members. It can also create a more organised treatment journey, as the hospital and insurer generally already have established processes for pre-authorisation, billing, and claim communication.

Nearby Network Hospitals Can Reduce Travel Time During Medical Emergencies

Medical emergencies often require quick action, and a long travel time can add strain to an already difficult situation. A hospital near home may reduce travel time, help the senior citizen reach medical attention sooner, and avoid the discomfort of a long journey when mobility is limited.

This matters not only in cases of sudden illness but also in situations where quick admission is important. In busy cities, traffic and distance can easily delay treatment, so nearby network access should be seen as an important part of policy selection.

Network Hospitals Can Make the Claim Process Easier

The claim process can be more difficult when treatment is received outside the insurer’s network. At a network hospital, the process is often clearer for pre-authorisation, document submission, billing, and communication with the insurer. This can reduce confusion during admission and discharge.

For senior citizens, a simpler process is important because treatment decisions should not be delayed by unnecessary paperwork or pressure. This also matters when families compare senior citizen coverage with broader family medical insurance needs and want easier claim support.

How to Check the Network Hospital List Before Buying a Policy

Before buying a policy, the network hospital list should be checked with the same discipline used for policy benefits. Start by seeing whether hospitals near the residence are actually included, rather than assuming well-known facilities are part of the network.

A hospital name alone is not enough if a different branch is listed. It is also important to see whether there is more than one nearby option. A wider local network can offer greater flexibility if one hospital is full, unavailable, or unsuitable for a particular treatment need.

Things to Review in the Network Hospital List

A long hospital list may look reassuring, but the real value depends on how relevant and accessible those hospitals are for senior care needs.

Distance from home and ease of reaching the hospital quickly
Availability of multi-speciality care within the nearby network
More than one local option for flexibility during admission
Updated hospital names, branches, and cashless eligibility details
Clear contact information for hospital desks or insurer support

Conclusion

When selecting senior citizen cover, the network hospital list should be treated as a core decision point, not a minor feature. Nearby hospitals can affect cashless access, emergency travel time, and the ease of managing claims when treatment is needed. A policy may seem strong in wording, yet feel less useful if suitable network hospitals are not close by. Careful review of local hospital access can lead to a more informed and dependable choice.

Smart Medical Coat Developed in Bhilai to Monitor Heart and Lung Health

News Desk — Thu, 19 Mar 2026 04:55:08 +0000

Research by Rungta International Skills University receives patent recognition by Government of India

In a major breakthrough in health technology, researchers at Rungta International Skills University in Bhilai have developed a smart medical coat that helps monitor heart and lung health in real-time. The research has received patent recognition by the Government of India, creating a major milestone in health technology emerging from Chhattisgarh.

The smart coat has been developed to monitor health parameters even when worn, helping identify major health issues related to heart, lung, and respiratory problems. The technology is expected to go beyond conventional methods of health check-ups, helping monitor health parameters continuously.

The technology was developed under the guidance of Pro Chancellor Dr. Sourabh Rungta, along with researcher Dr. Sandeep Bhad, who played an integral part in this research.

Continuous Monitoring Using Wearable Technology

The smart coat utilizes wearable technology by incorporating sensors that allow for continuous monitoring of a user’s health while wearing a coat that is comfortable for daily activities. Once the user puts on the coat, the smart coat continuously monitors key health indicators such as heart rate, breathing patterns, levels of oxygen in the blood, and body temperature.

The smart coat is then able to identify unusual patterns in the user’s health indicators and send early warning signals for any possible health risks that may occur.

According to the research team that developed the smart coat, the device has the ability to detect early signs of any possible health risks that may occur due to respiratory distress, irregular heart beats, and fluctuations in levels of oxygen in the blood. This device has the ability to help individuals who need constant monitoring of their health, especially the elderly.

Solar-Powered Sensors and Real-Time Data

The smart medical coat has biosensors that utilize solar fabric technology. The technology allows the biosensors to operate while the smart medical coat is being worn. The biosensors collect data and process it using a digital monitoring system.

The technology can monitor unusual changes in a person’s physical condition. The system can send alerts when necessary. The technology can also be useful for remote monitoring. The technology can help doctors and caregivers monitor patients effectively.

Clinical Trials in the Next Phase

The research team is currently preparing for clinical trials, which will be the next step toward evaluating the effectiveness of the smart medical coat in real-world healthcare settings. The proposal will be submitted to relevant regulatory authorities for approval before wider deployment.

Experts believe that wearable technologies like the smart coat could play a significant role in preventive healthcare, helping detect medical conditions early and reducing the need for emergency interventions.

The development reflects the growing emphasis on innovation-driven research in Indian universities and highlights the potential of academic institutions in contributing to the future of digital healthcare.

Your Ozempic Will Get Cheaper From March 21 — Here Is by How Much and Why

Aditya Bhagchandani — Tue, 17 Mar 2026 07:21:53 +0000

If you or someone in your family takes Ozempic or Wegovy for diabetes or weight management, mark March 21 in your calendar. That is the day Novo Nordisk’s last remaining Indian patent on semaglutide expires — and the day a flood of cheaper Indian-made alternatives hits the market, potentially cutting your monthly medicine bill by half or more.

Here is everything you need to know, explained simply.

What Is Semaglutide and Why Is It So Expensive Right Now

Semaglutide is the active ingredient in Ozempic and Wegovy — two drugs made by Danish pharmaceutical giant Novo Nordisk that have transformed the treatment of type 2 diabetes and obesity globally. The drug works by mimicking a hormone that regulates blood sugar and appetite, producing significant improvements in both conditions with a once-weekly injection.

It became one of the fastest-selling drugs in pharmaceutical history. Novo Nordisk briefly became the most valuable company in Europe on the back of its success. Global demand created shortages at pharmacies across the United States and Europe. Celebrities and executives openly discussed using it for weight loss. The word Ozempic entered everyday vocabulary.

In India, it has been available — but at a price that put it out of reach for most patients. A monthly starter dose currently costs approximately ₹10,000 to ₹15,000 depending on strength and where you buy it. For a chronic condition requiring indefinite treatment, that is ₹1.2 lakh to ₹1.8 lakh per year — entirely out of pocket since most Indian insurance policies do not cover anti-obesity medications.

India has over 100 million adults living with diabetes. The overwhelming majority of them have never been able to afford the most effective available treatment for their condition.

That changes on March 21.

What Happens on March 21

Novo Nordisk’s last remaining Indian patent covering semaglutide expires on March 20. From March 21, any Indian pharmaceutical company with regulatory approval is free to manufacture and sell its own version of semaglutide in India.

More than a dozen companies have been preparing for exactly this day for months — obtaining approvals from the Drug Controller General of India, completing bioequivalence studies, building manufacturing capacity, registering brand names, and training sales forces. They are ready. The moment the patent clock hits midnight on March 20, they launch.

Industry analysts expect that once generics enter from March 21, prices could drop to ₹3,500 to ₹4,000 for starter doses. That is a 50 to 65% reduction from current Novo Nordisk pricing — a saving of ₹4,000 to ₹6,000 per patient per month, or ₹50,000 to ₹70,000 per year for someone on a continuous maintenance dose.

Early competition may push discounts even further, with some estimates suggesting reductions of 50 to 60% in the initial phase. Over time, prices could further correct as low as 70 to 75% from current levels as the market becomes increasingly crowded.

Which Companies Are Launching and Under What Names

The list of confirmed or expected Day 1 launchers reads like a who’s who of Indian pharma.

Sun Pharmaceutical Industries launches two brands — Sematrinity for type 2 diabetes and Noveltreat for chronic weight management — after receiving DCGI approval earlier this year. Sun committed to launching only after patent expiry in undertakings given to the Delhi High Court.

Dr Reddy’s Laboratories enters under the brand name Obeda, having obtained regulatory clearance and trademarked the name. The company has been permitted by courts to manufacture and export semaglutide and pivots to domestic sales from March 21. Dr Reddy’s is simultaneously building a broader ecosystem that includes Obesity Centres of Excellence, physician education, nutritional products tailored for GLP-1 users and structured patient-support initiatives — positioning itself as more than just a pill supplier.

Zydus Lifesciences launches three brands — Semaglyn, Mashema and Alterme — with a key differentiator that no other Indian company currently offers. Zydus has developed an innovative, adjustable single-pen device that allows patients to seamlessly select and administer varying dose strengths from a single unit, significantly enhancing patient adherence, maximising convenience and drastically reducing the overall cost of therapy. On March 17, Zydus also signed a licensing agreement with Lupin, which will market the same product under the brands Semanext and Livarise — giving Zydus’ molecule access to Lupin’s extensive network of cardiometabolic physicians and distributors.

Alkem Laboratories, Natco Pharma in partnership with Eris Lifesciences, Mankind Pharma, Cipla and Ajanta Pharma have all indicated launch plans through regulatory filings, investor communications and public statements. Industry executives expect an initial wave of more than a dozen brands within weeks, with dozens more following over the year.

Will the Generic Versions Work as Well as Ozempic

This is the question every patient and doctor will be asking, and it deserves a direct answer.

Generic drug approvals in India require bioequivalence studies — clinical tests demonstrating that the generic version is absorbed and distributed in the body in the same way as the original innovator product, producing the same therapeutic effect. Every company launching semaglutide generics in India has completed these studies and received DCGI approval on that basis.

The active molecule — semaglutide — is identical in every approved generic. What differs between brands is the delivery device, the excipients used in the formulation, the manufacturing facility standards, and the cold chain management during distribution. These factors affect quality and reliability in practice even when the active ingredient is the same.

Patients switching from Ozempic to a generic version should do so under their doctor’s guidance, particularly if they are mid-titration or managing a complex diabetes regimen. The chemistry is the same. The practical experience of the injection device and the reliability of the supply chain may differ between manufacturers.

What This Means for the 100 Million Indians With Diabetes

India has the second largest diabetic population in the world after China — over 100 million adults, projected to reach 150 million by 2050 according to the International Federation of Diabetes. The overwhelming majority manage their condition with older, cheaper medications because the most effective newer therapies were priced beyond reach.

The India GLP-1 receptor agonist market was estimated at USD 110.55 million in 2024 and is projected to grow at a CAGR of 34.3% from 2025 to 2030. That growth projection was made before generic entry. Post March 21, with prices halved or more, the actual growth rate could be significantly higher as millions of patients who were previously priced out begin accessing treatment for the first time.

The obesity angle is equally significant. India’s weight management market was valued at $27.4 billion in 2025 and is projected to grow to $56.79 billion by 2034. Semaglutide at ₹3,500 per month is a fundamentally different product in a fundamentally different market than semaglutide at ₹10,000 per month. The patient population that can realistically sustain treatment at the lower price point is many times larger.

What Novo Nordisk Does Now

For Novo Nordisk, India is an early test of the global GLP-1 patent cliff that will eventually arrive in every market. The company responded before March 20 by cutting Wegovy’s starter dose price by 37% to approximately ₹10,000 — a preemptive move that acknowledged what was coming without being able to stop it.

The innovator’s long-term position in India will depend on physician loyalty built over years of medical education and relationship management, brand trust among patients who associate Ozempic with the original clinical trial data, and any manufacturing quality perception advantages the original product carries over newer generic entrants.

These are real advantages. They are not sufficient to prevent price erosion. They are sufficient to maintain a premium positioning among the subset of patients and physicians who prioritise brand trust over cost — which in India’s predominantly out-of-pocket market is a smaller subset than in reimbursed healthcare systems.

The One Thing to Watch After March 21

The price drop on March 21 is the headline. The story that develops over the following 12 months is more important: whether patients who start semaglutide at ₹3,500 per month actually stay on it long enough to get the clinical benefits the drug is capable of delivering.

A University of Oxford study published in the British Medical Journal in January 2026 found that weight regain after stopping weight-loss drugs occurred faster than after lifestyle-based programmes, with participants regaining weight within about 1.7 years of discontinuation. Affordability gets patients onto the drug. Physician support, lifestyle counselling and patient education keep them on it long enough for the drug to work. The companies building those support structures around their generic launches — Dr Reddy’s Obesity Centres of Excellence, Zydus’ reusable pen device that reduces the friction of daily adherence — are not just doing good medicine. They are building the commercial moats that survive the price war.

Your Ozempic gets cheaper from March 21. Whether it changes India’s diabetes epidemic depends on what happens in the months after.

One Patent Expiry on March 20 Could Make India’s Most Effective Diabetes Drug Affordable for the First Time — Here Is the Full Story

Aditya Bhagchandani — Tue, 17 Mar 2026 07:13:29 +0000

The drug that made Novo Nordisk briefly the most valuable company in Europe, created global shortages, and turned the word “semaglutide” into dinner table conversation is about to get a lot cheaper in India. The patent expires on March 20. The generics arrive on March 21. And the price you pay for the same molecule drops by half — potentially within days.

This is not a gradual market shift. It is a cliff edge. One day Novo Nordisk has exclusivity. The next day it does not. And on that next day, more than a dozen Indian pharmaceutical companies are ready at the starting line with approved products, branded names, and distribution networks built for exactly this moment.

What Is About to Change and Why It Matters

Semaglutide — sold by Novo Nordisk as Ozempic for type 2 diabetes and Wegovy for chronic weight management — currently costs Indian patients approximately ₹10,000 to ₹15,000 per month for starter doses depending on strength and channel. That price has kept one of the most effective diabetes and obesity drugs in medical history out of reach for the overwhelming majority of India’s more than 100 million diabetic adults.

Industry analysts expect that once generics enter from March 21, prices could drop to ₹3,500 to ₹4,000 for starter doses. That is a saving of ₹4,000 to ₹6,000 per patient per month — or ₹50,000 to ₹70,000 per year — for a chronic condition that requires indefinite treatment. At those prices, semaglutide stops being a drug for wealthy urban professionals and starts being a drug for India.

The scale of the population waiting for this moment is staggering. India has over 100 million individuals living with diabetes today, projected to surge to more than 150 million by 2050 according to the International Federation of Diabetes India country report. Obesity rates in urban and semi-urban India are rising sharply. The India GLP-1 receptor agonist market was estimated at USD 110.55 million in 2024 and is projected to grow at a CAGR of 34.3% from 2025 to 2030. Price was the primary barrier between that growth rate and an explosion. March 21 removes the barrier.

The Companies at the Starting Line

Sun Pharmaceutical Industries has confirmed two branded options — Sematrinity for type 2 diabetes and Noveltreat for chronic weight management. The company received DCGI approval earlier this year and has committed to launch only after patent expiry, in line with undertakings given to the Delhi High Court.

Dr Reddy’s Laboratories is preparing a Day 1 entry under the brand name Obeda, having obtained regulatory clearance and trademarked the brand. The company has previously been permitted by courts to manufacture and export semaglutide and is expected to pivot immediately to domestic sales once the patent lapses. Dr Reddy’s is planning a rollout across 87 countries, with Day 1 launches in India and Brazil as patents expire.

Zydus Lifesciences is arguably the most strategically differentiated entrant. The company launches three brands — Semaglyn, Mashema and Alterme — and on March 17 announced a licensing and co-marketing agreement with Lupin, which will sell the same molecule under the brands Semanext and Livarise. Five brands from two companies, sharing one product, combining Zydus’ indigenously developed reusable adjustable pen device with Lupin’s extensive cardiometabolic prescriber network. Unlike existing treatments that require patients to purchase multiple single-dose pens as they titrate their dosage, Zydus’ innovative adjustable single-pen device allows patients to seamlessly select and administer varying dose strengths from a single unit, significantly enhancing patient adherence and drastically reducing the overall cost of therapy.

Alkem Laboratories, Natco Pharma, Eris Lifesciences, Mankind Pharma, Ajanta Pharma and Cipla have either confirmed approvals or indicated launch plans through investor calls and regulatory disclosures. Industry executives expect an initial wave of more than a dozen brands within weeks, with dozens more following over the year.

What This Does to Novo Nordisk

For Novo Nordisk, India becomes one of the first major markets where Ozempic loses exclusivity — an early and closely watched test of how quickly generics erode pricing power in the GLP-1 segment globally. The company responded before the patent fell by cutting prices preemptively. Wegovy’s starting dose price was reduced by 37% in November to approximately ₹10,000 per month. It was not enough to deter the generics. It was enough to signal that Novo Nordisk understood what was coming.

The innovator’s playbook in this situation is well established from previous blockbuster patent expiries: defend the brand through physician relationships, differentiate on quality perception, and accept that volume shifts to generics while protecting premium positioning among the most adherent patients. How effectively Novo Nordisk executes that playbook in India will be watched by every pharmaceutical company globally as the GLP-1 patent cliff begins its global progression.

The Bigger Picture: What ₹3,500 Semaglutide Does to India

The price reduction that March 21 initiates is not just a pharma market story. It is a public health story and an economic story simultaneously.

India’s weight management market was valued at $27.4 billion in 2025 and is projected to grow to $56.79 billion by 2034. A significant portion of that growth has been constrained by the cost of the most effective available interventions. When semaglutide drops from ₹10,000 to ₹3,500 per month, millions of patients who were previously priced out of the most effective available diabetes and obesity treatment gain access to it. The health system implications — reduced diabetes complications, lower cardiovascular event rates, reduced hospitalisation from obesity-related conditions — are measurable in population health terms over five to ten years.

Industry analysts say the wave of semaglutide launches marks an important inflection point for Indian pharma, with the planned entries showing a deliberate shift into complex peptide manufacturing and high-value injectable therapies. Scaling peptide synthesis and sterile injectable infrastructure strengthens India’s competitiveness in regulated markets and helps diversify revenues away from commoditised oral generics.

“India is facing one of the world’s fastest-growing diabetes burdens, and addressing this challenge requires continuous innovation and strong partnerships,” said Kartik Rajendran, Managing Director of Abbott India.

The Warning: Not Every Generic Is the Same

The arrival of a dozen-plus semaglutide brands does not mean every brand is equally reliable. Generic drug approvals in India require bioequivalence studies demonstrating that the generic performs the same way as the original — but the quality of manufacturing, cold chain management and device reliability varies across manufacturers.

Physicians and patients choosing between fifteen brands of the same molecule at similar prices will be making decisions based on trust, physician recommendation and perceived quality rather than clinical differentiation. The companies that invest in physician education, patient support programmes and pharmacovigilance in the first six months after launch will build the prescriber relationships that determine long-term market share in a commodity-priced segment.

March 21 is the day the price falls. The companies that win the decade that follows are the ones that understand it is only the beginning.

Explainer: The Semaglutide opportunity in India and who leads the race among Indian companies

Aditya Bhagchandani — Tue, 17 Mar 2026 06:46:47 +0000

The drug that made Novo Nordisk briefly the most valuable company in Europe, created global shortages, and put the word “semaglutide” into everyday conversation has just gone off patent in India. As of March 21, 2026, the molecule behind Ozempic and Wegovy is open for competition — and Indian pharma is treating it like the starting gun of the most consequential race in the industry’s history.

On March 17, Zydus Lifesciences and Lupin announced a licensing and co-marketing agreement that brings the total number of brands entering the Indian semaglutide market to five from these two companies alone — Semaglyn, Mashema and Alterme from Zydus, and Semanext and Livarise from Lupin. It is the latest move in what industry insiders are calling a gold rush, and it illustrates exactly how the battle for India’s semaglutide market will be won — not just on price, but on distribution, device innovation and physician relationships.

Zydus and Lupin sign agreement to co-market Semaglutide injection in India

What Semaglutide Is and Why It Matters

Semaglutide is a GLP-1 receptor agonist — a class of drug that mimics a hormone called glucagon-like peptide-1, which regulates blood sugar and appetite. It was originally developed by Novo Nordisk for type 2 diabetes under the brand name Ozempic. At higher doses, it became Wegovy for chronic weight management. The results in both indications were dramatic enough to create waiting lists at pharmacies across the United States and Europe.

India’s weight management market was valued at $27.4 billion in 2025 and is projected to grow to $56.79 billion by 2034. Goldman Sachs has estimated the global anti-obesity drug market could grow to over $100 billion in the next decade. The India GLP-1 receptor agonist market was estimated at USD 110.55 million in 2024 and is projected to grow at a CAGR of 34.3% from 2025 to 2030.

India has one of the world’s largest diabetes burdens — approximately 8.9 crore adults with the condition — and obesity rates in urban areas are rising sharply. The market was waiting for an affordable version of semaglutide. As of March 21, it has one. It will soon have dozens.

The Patent Expiry: What Just Opened Up

Semaglutide’s patent expired on March 20, clearing the path for more than half a dozen companies including Sun Pharma, Zydus Lifesciences, Dr Reddy’s and Natco Pharma to enter the market from Day 1, March 21.

In India, patents covering semaglutide’s composition and delivery expired or will expire by March 2026, allowing local drugmakers to enter the highly lucrative anti-obesity and diabetes space with their own versions. More than two dozen Indian pharmaceutical firms are preparing to launch semaglutide-based generics under a bewildering array of names.

Until now, semaglutide therapies were sold at high prices, limiting access for many patients. A monthly starter dose costs close to ₹10,000. Industry analysts expect that once generics enter from March 21, prices could drop to ₹3,500 to ₹4,000 for starter doses.

The Prize: How Big Is This Really?

The expiration of semaglutide’s patent across India, emerging economies and select regulated markets like Canada and Brazil could unlock a revenue pool exceeding ₹50,000 crore for generic drugmakers over the next 12 to 15 months.

The Indian market is expected to see a ₹1,000 crore to ₹2,000 crore incremental revenue opportunity in the branded formulation space for FY27 alone. India may see a sharp rise in adoption of GLP-1 therapy among diabetics, driven by an affordable price point potentially 30 to 50% lower than current levels. Over time, prices could further correct as low as 70 to 75% from current levels.

Experts say that with patent expiry, the generic semaglutide opportunity in India alone could be worth over ₹50 billion, about USD 600 million, in the coming years as multiple players enter the segment.

The Competitors: Who Is Racing and How

This is not a conventional generic drug entry where price is the only variable. Every serious player in the Indian semaglutide race has a differentiated strategy — because in a market where dozens of brands will eventually compete, the ones that win will do so on physician relationships, delivery device innovation, patient support programmes and distribution reach.

Zydus Lifesciences is the most strategically differentiated entrant. A critical differentiator of Zydus’ semaglutide offering is its novel, indigenously developed drug delivery system. Unlike existing treatments that require patients to purchase multiple single-dose pens as they titrate their dosage, Zydus plans to introduce an innovative, adjustable single-pen device that allows patients to seamlessly select and administer varying dose strengths from a single unit, significantly enhancing patient adherence, maximising convenience and drastically reducing the overall cost of therapy. The company launched three brands — Semaglyn, Mashema and Alterme — and has now added Lupin’s distribution muscle through the March 17 licensing agreement.

Dr Sharvil Patel’s articulation of the Zydus thesis is worth quoting in full: “We are not just planning to bring a critical therapy to market, we are aiming to elevate the standard of care. By introducing a first-of-its-kind drug delivery mechanism in India, we plan to simplify the treatment.”

Dr Reddy’s Laboratories is positioning its entry around what it calls a “beyond-the-pill” strategy. The company plans to launch generic semaglutide on Day 1 and is simultaneously building a broader ecosystem that includes Obesity Centres of Excellence, physician education, nutritional products tailored for GLP-1 users and structured patient-support initiatives. Dr Reddy’s Ramana acknowledged the pricing reality directly: “If it is not competitive, and being an out-of-pocket product, then the usage of the product would not be as much.”

While Dr Reddy’s is planning a rollout of semaglutide across 87 countries next year, with Day 1 launches in India and Brazil as patents expire, Cipla is targeting first-wave launches through a mix of in-house and partner filings. Players like Ajanta Pharma and Emcure have already announced partnerships with Biocon and Novo Nordisk to commercialise semaglutide brands in India and international markets.

Sun Pharmaceutical Industries has received regulatory approval from India’s drug regulator to manufacture and market semaglutide and plans to launch the product in multiple dose strengths through user-friendly delivery devices. Natco Pharma has partnered with Eris Lifesciences to bring a generic version to market, combining manufacturing strength with strong presence in the diabetes segment.

The March 17 agreement between Zydus and Lupin is more than a routine licensing deal. It is a recognition by both companies that winning the semaglutide market requires combining Zydus’ product development and device innovation with Lupin’s extensive physician reach and distribution network in the cardiometabolic segment.

Nilesh Gupta, Managing Director of Lupin, described the rationale clearly: “Our partnership with Zydus to market semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases. As GLP-1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs.”

Lupin brings particular strength in the cardiology and endocrinology prescriber segments — precisely the physicians who will drive semaglutide adoption. Zydus brings the product, the device and the regulatory approvals. Under the agreement, Lupin pays Zydus upfront licensing fees and milestone payments on achieving pre-defined milestones.

Nomura’s Head of Equity Research Saion Mukherjee has identified Dr Reddy’s Laboratories as a prime contender, citing its proficiency in navigating complex regulatory pathways and its established international market presence as critical advantages, including an extensive pipeline of GLP-1 receptor agonists serving both diabetes and obesity treatment segments globally.

Sun Pharmaceutical Industries, with a market capitalisation of approximately ₹4.40 trillion and a P/E ratio of 39.72 as of March 11, 2026, appears positioned to leverage its scale. Zydus Lifesciences, with a lower P/E of 18.62 and market cap of around ₹0.92 trillion, presents a potentially more undervalued profile.

Industry analysts say the wave of semaglutide launches marks an important inflection point for Indian pharma. “The planned entry by companies such as Zydus, Dr Reddy’s and Eris show a deliberate shift into complex peptide manufacturing and high-value injectable therapies,” said Salil Kallianpur, pharma analyst. “GLP-1 drugs are among the fastest-growing global therapy segments. Indian companies positioning themselves here point to a structural upgrade in capability and ambition.”

Kallianpur added: “Scaling peptide synthesis and sterile injectable infrastructure strengthens India’s competitiveness in regulated markets and helps diversify revenues away from commoditised oral generics. If executed well, this could reinforce India’s standing not merely as a volume generics supplier, but as a reliable hub for complex, high-technology therapeutics.”

The opportunity is real. So are the risks.

In India, concerns over the approval of GLP-1 receptor agonists reached the Delhi High Court. Fitness entrepreneur Jitender Chouksey filed a public interest litigation questioning the approval of GLP-1 receptor agonists for obesity without large India-specific clinical trials. The regulatory and legal environment remains a watch point.

A University of Oxford study published in the British Medical Journal in January 2026 found that weight regain after stopping weight-loss drugs occurred faster than after lifestyle-based programmes. Participants regained weight within about 1.7 years of discontinuation, with cardiometabolic gains reversing within roughly 1.4 years. Long-term adherence is therefore a genuine clinical and commercial question — semaglutide works while patients take it, but discontinuation rates in price-sensitive markets may be higher than in the clinical trial populations.

Industry watchers anticipate that market dynamics will shift from premium mono-brand dominance to fragmented branded generics wars, where multiple manufacturers seek share through pricing, pen delivery innovations and distribution networks. Analysts anticipate potential price reductions of 80 to 90% for these treatments — which is excellent for patients but compresses the revenue opportunity significantly for manufacturers competing on price alone.

The companies that survive the price war will be those that have built physician relationships, patient support infrastructure, delivery device advantages and export market access that commodity pricing cannot erode. Zydus, with its pen device advantage and the Lupin distribution partnership announced on March 17, has built the most defensible early position. Dr Reddy’s ecosystem approach gives it a differentiated doctor-facing story. Sun’s scale gives it manufacturing cost advantages that matter when margins compress.

Semaglutide was originally developed and marketed by Novo Nordisk under brands such as Ozempic and Wegovy and has become one of the fastest-growing drug categories in the world due to its strong results in blood sugar control and weight reduction. India spent years watching that revolution happen elsewhere, at prices that put it out of reach for the vast majority of its diabetic and obese population.

This article is for informational purposes only.

Rising Air Pollution May Contribute to Male Infertility: Study!

Riddhima Jain — Tue, 17 Mar 2026 05:15:43 +0000

A nationwide research study by Indira IVF suggests worsening air pollution could be contributing to declining sperm DNA health among men in urban areas.

The study found that men living in regions with AQI levels above 151 recorded an 11% drop in normal sperm integrity compared to those in cleaner environments.

Researchers analysed 3,222 men aged between 21 and 40 across 120 Indira IVF centres nationwide, focusing specifically on sperm DNA integrity rather than traditional semen parameters.

According to the study, 69.3% of sperm samples were normal in areas with AQI levels between 50 and 100, but the proportion declined as pollution levels increased.

In moderately polluted regions with AQI levels between 101 and 150, normal sperm levels fell by 8.8%, while in highly polluted areas (AQI above 151) the decline reached 11%.

Commenting on the research, Dr. Kshitiz Murdia, CEO & Whole-Time Director, Indira IVF Hospital Limited, said, “The implications of these findings go beyond conception challenges. Prolonged exposure to pollution can affect sperm DNA integrity, which may also affect foetal development. In this study, patients were categorised based on sperm DNA fragmentation scores, with normal defined as less than 25% fragmentation and abnormal as greater than 25%, allowing us to closely assess how different air quality levels impact sperm chromosome integrity. Our observations suggest that rising air pollution levels can serve as a reliable indicator for disturbed sperm DNA fragmentation, significantly impacting Sperm DNA integrity, more-so in high-pollution urban centres.”

Dr. Vipin Chandra, Chief of Clinical and Lab Operations, Indira IVF Hospital Limited said, “We analysed a statistically significant cohort of 3,222 men aged 21 to 40 across 120 Indira IVF centres nationwide. Rather than focusing on conventional semen parameters such as sperm count or motility, the study specifically examined sperm DNA integrity. This enabled a more precise assessment of how exposure to air pollution directly impacts the genetic structure of sperm, offering deeper insight into an often-overlooked contributor to male infertility.”

These findings align with the growing burden of male infertility observed in recent years in highly polluted urban areas.

Glenmark Pharmaceuticals to launch Potassium Phosphates Injection in March 2026

Business Desk — Mon, 16 Mar 2026 03:13:32 +0000

Glenmark Pharmaceuticals Inc., USA, is set to launch its Potassium Phosphates Injection USP in March 2026, offering single-dose vials and pharmacy bulk package vials. The product is bioequivalent to Fresenius Kabi‘s reference drug.

The Potassium Phosphates Injection USP will be available in 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL single-dose vials, and 150 mmol P / 220 mEq K per 50 mL pharmacy bulk package vials. According to IQVIA sales data, the market for these injections achieved annual sales of approximately $50.7 million as of January 2026.

Marc Kikuchi, President & Business Head, North America, commented on the launch, expressing Glenmark’s commitment to expanding its product portfolio within the institutional channel and providing affordable alternatives for patients.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Comparing Benefits: Individual Best Health Insurance vs. Best Health Insurance Policy for Family

News Desk — Thu, 12 Mar 2026 06:46:59 +0000

Choosing between an individual plan and a family floater can shape how well medical cover matches household needs, future expenses, and renewal ease over the years. For anyone comparing the best health insurance options, the difference is not only about the premium but also about how protection is arranged for every insured member.

This article explains how individual and family health insurance plans differ across coverage, cost, flexibility, claim use, and policy management.

Coverage Structure: Dedicated Vs Shared Sum Insured

An individual health insurance plan generally assigns a separate sum insured to one insured member, so the full coverage remains reserved for that person alone. A family floater, by contrast, usually offers one shared sum insured for all covered members under a single policy.

This difference matters because dedicated cover protects each member separately, while shared cover is built for collective use. The best health insurance policy for family needs should therefore be assessed by the number of insured members, their age mix, and the possibility of multiple hospitalisations in the same policy year.

Premium Structure and Cost Efficiency

Premiums for individual plans are usually calculated separately for each insured person, so the total outgo may rise when several members need cover. Family floater plans often seem more cost-efficient when the household is younger, and claims are expected to be limited or spread out.

Cost efficiency also depends on the sum insured, the age of the eldest member, and the balance between immediate savings and long-term suitability.

Flexibility and Policy Customisation

Individual policies often offer greater flexibility to tailor coverage to a person’s needs, health priorities, and preferred level of protection. This can suit households where members need different coverage levels or benefit choices. Family floater plans, while convenient, usually apply one policy structure across all insured members, which can reduce personalisation to some extent.

Claim Utilisation and Risk Distribution

Claim utilisation works differently under both formats. In an individual plan, one member’s claim does not reduce the protection available to another person because each policy has its own limit. In a family floater, a single large claim can reduce the remaining shared sum insured for others in the same year.

This affects risk distribution significantly. Households with varied age groups or differing health concerns may need to consider whether shared risk remains comfortable when more than one member may need treatment within a limited period.

Policy Management and Renewal Simplicity

From an administrative perspective, family floater plans are often easier to manage because a single policy document, a single premium payment cycle, and a single renewal date can cover multiple members. This can reduce paperwork and simplify annual tracking.

Individual plans, on the other hand, may involve separate renewals, separate records, and closer monitoring across policies. Even so, some people may prefer that extra effort if it gives better control over coverage for each insured member.

Comparing the Benefits of Individual and Family Health Insurance Plans

Both options serve different protection goals, so the comparison should focus on how cover behaves in practice rather than on headline pricing alone.

Feature	Individual Health Insurance	Family Health Insurance
Sum Insured	Separate for each insured member	Shared among all insured members
Premium Basis	Calculated per individual	Calculated for the family unit, usually based on member profiles
Cost Efficiency	Maybe higher for multiple members	Often more economical for younger families
Customisation	Higher scope for person-specific cover	More uniform structure across members
Claim Impact	One person’s claim does not affect another’s cover	One claim may reduce the balance available to others
Renewal Management	Multiple policies may need tracking	A single policy is usually simpler to renew
Suitability	Better where needs differ by person	Better where one shared cover suits the household

Conclusion

Comparing individual and family health insurance plans requires more than a quick look at premium figures. The choice depends on how coverage is allocated, how claims may affect available protection, and how easily the policy can be managed over time. Individual plans offer separation and greater tailoring, while family floaters offer simplicity and shared cover. A careful review of these differences can support a more suitable decision for the household’s present and future needs.

Hearing Aid Technology: How Modern Features Are Transforming User Experience

News Desk — Sat, 07 Mar 2026 18:36:52 +0000

If you still picture bulky devices that only “make things louder,” modern hearing aids will surprise you. Today’s models are small, smart, and designed to fit real life – busy streets, family conversations, office calls, and weekend celebrations. With better sound processing, connectivity, and support options like an online hearing test, people can move from “just managing” hearing loss to genuinely enjoying clearer, calmer listening.

From Amplification to Personalised Sound

The biggest change is that hearing aids no longer amplify everything equally. They analyse sound in real time and prioritise what you want to hear. Instead of turning the world up, they shape it.

Key upgrades you’ll notice:

Speech enhancement that lifts voices above background noise
Directional microphones that focus on the person in front of you
Automatic scene detection that shifts settings between home, traffic, or a restaurant
Feedback control that reduces whistling without dulling clarity

Smarter Fitting and Fine-Tuning

Better hardware is only half the story. The fitting process has become more precise, which directly improves comfort and understanding. Professionals can map your hearing profile and match it to your daily needs. Many fittings use real-ear measurement to verify sound accurately.

Many brands also offer app-based adjustments so you can:

Reduce noise in a crowded market
Increase speech focus during a family dinner
Save preferred settings for repeat situations

Some people begin with an online hearing test to understand if there’s a likely issue before booking an in-person assessment. While it isn’t a final diagnosis, it can be a useful first step, especially if you’re unsure whether you need help.

Connectivity That Fits Indian Lifestyles

Wireless streaming has transformed convenience. Modern hearing aids can connect to phones and other devices, making tasks easier.

Popular use cases include:

Clearer phone calls, including on popular calling apps
Streaming music, videos, or news without raising the volume for everyone at home
Hands-free listening during work calls or commute time
Quick control via an app, without touching the device

For many users, this connectivity is what makes the devices feel like part of a modern lifestyle, not a medical accessory.

Rechargeables and Power Management

Battery stress is a real barrier for first-time users. Rechargeable hearing aids have helped by removing the constant worry of spare cells and disposal. A charging case on the bedside table can feel as normal as charging your phone.

Look for features such as:

Full-day power on one charge for routine use
Fast-charge options for short top-ups
Low-battery alerts that show up on your phone

If you travel often, compact charging cases are useful on trains or flights.

Comfort, Discretion, and Durability

User experience is also physical. Better design means lighter shells, improved ear-tip options, and greater sweat- and dust-resistance, which is vital in humid summers and long commutes.

Modern designs may include:

Smaller behind-the-ear bodies with thin tubes
In-ear styles that sit discreetly
Moisture protection for active days

Comfort matters because consistent wear is what delivers consistent results.

Safety and Health Features

Some newer models go beyond hearing support. They can monitor device usage patterns and encourage better habits. A few even include fall alerts or basic activity tracking, depending on the model and app support.

More importantly, today’s processing can reduce listening effort, which many users describe as “less tiring” by evening. When sound feels easier, social confidence often follows.

Getting Started: Knowing When to Act

If you frequently ask people to repeat themselves, struggle in groups, or feel the TV volume is creeping up, don’t ignore it. Start with an online hearing test if you want a quick screening, then follow up with a qualified hearing professional for a full evaluation and device recommendation.

The right hearing aids are the ones that match your hearing needs, comfort preferences, and daily routine – not the most expensive pair on the shelf.

Conclusion

Technology is making hearing aids more natural, more connected, and far easier to live with. With smarter sound processing, simple personalisation, and entry points such as an online hearing test, users can take control early and enjoy clearer conversations in every part of their lives.

Aurobindo Pharma subsidiary launches Pomalidomide Capsules in US market, targets $3.3 billion opportunity

Aman Shukla — Wed, 04 Mar 2026 06:45:59 +0000

Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Eugia Pharma Specialities Limited, has launched Pomalidomide Capsules in strengths of 1 mg, 2 mg, 3 mg and 4 mg in the United States market. The launch marks a significant expansion of the company’s oncology portfolio in the highly competitive US generics market.

The newly launched product is the generic equivalent of Pomalyst® Capsules, a drug marketed by Bristol Myers Squibb. Eugia Pharma was among the First-to-File (FTF) ANDA applicants for the product, providing the company with a strategic entry into a large-value therapeutic segment.

According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately $3.3 billion in the United States, highlighting the strong commercial potential for the generic version.

Pomalidomide is a third-generation immunomodulatory drug (IMiD) primarily used in the treatment of relapsed or refractory multiple myeloma, typically administered in combination with dexamethasone and sometimes bortezomib. The drug is also indicated for the treatment of AIDS-related Kaposi sarcoma, making it an important therapy in oncology and immunology.

The capsules will be manufactured at Eugia Unit-I, one of the company’s facilities dedicated to oncology and specialty pharmaceutical products.

Hyderabad-headquartered Aurobindo Pharma is a global pharmaceutical company engaged in the development, manufacturing and commercialization of generic medicines, specialty pharmaceuticals and active pharmaceutical ingredients (APIs). The company sells its products in more than 150 countries worldwide.

Aurobindo Pharma currently operates over 30 manufacturing and packaging facilities approved by major global regulatory authorities including the USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC and Brazil ANVISA.

Natco Pharma launches Generic Pomalidomide Capsules in US market

Aman Shukla — Tue, 03 Mar 2026 05:08:59 +0000

Natco Pharma Limited (BSE: 524816 | NSE: NATCOPHARM) has announced the launch of Pomalidomide Capsules in the United States in partnership with Breckenridge Pharmaceutical, Inc.. The product is a generic version of Pomalyst, originally marketed by Celgene.

Pomalidomide Capsules are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy. The drug is also approved for the treatment of AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma.

The capsules are available in 1mg, 2mg, 3mg, and 4mg strengths and will be distributed primarily through specialty pharmacies and clinics across the US. Pomalidomide is a thalidomide analogue widely used in advanced-stage multiple myeloma treatment.

According to industry sales data, Pomalidomide Capsules in the US recorded estimated sales of USD 3.2 billion for the 12-month period ending September 2025. The significant market size underscores the commercial opportunity for generic manufacturers entering this segment.

Natco Pharma stated that, based on information made available by the US Food and Drug Administration, it believes it has secured 180 days of shared exclusivity for the product in the US market. This exclusivity period could provide a competitive advantage during the initial phase of commercialization.

Caplin Point subsidiary secures USFDA final approval for Desmopressin Acetate Injection ANDA

Aman Shukla — Sat, 28 Feb 2026 06:33:39 +0000

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited (BSE: 524742 | NSE: CAPLIPOINT), has secured final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Desmopressin Acetate Injection USP.

The approval covers 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials. The product is a generic therapeutic equivalent of the Reference Listed Drug, DDAVP Injection, 4 mcg/mL, marketed by Nordic Pharma Inc. under NDA 018938.

Desmopressin Acetate Injection is prescribed for the treatment of haemophilia A, von Willebrand disease, and central diabetes insipidus. The drug plays an important role in controlling bleeding episodes and regulating urine production in patients suffering from these conditions. Its clinical relevance in managing rare bleeding disorders and endocrine-related conditions makes it a critical injectable therapy in hospital and specialty care settings.

According to IQVIA (IMS Health) data, the US market for Desmopressin Acetate Injection USP, 4 mcg/mL, reported sales of approximately $26 million for the 12-month period ending December 2025. The approval enables Caplin Steriles to enter this established injectable segment in the United States and strengthens its presence in the regulated US generics market.

Zydus Lifesciences secures USFDA final approvals for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg

Aman Shukla — Sat, 28 Feb 2026 05:51:06 +0000

Zydus Lifesciences Limited has received final approvals from the United States Food and Drug Administration (USFDA) for two generic products — Ivermectin Tablets USP, 3 mg, and Dapsone Tablets USP in 25 mg and 100 mg strengths — further strengthening its footprint in the United States generics market.

The approval for Ivermectin Tablets USP, 3 mg, references the USRLD Stromectol. Ivermectin is a prescription anti-parasitic medication primarily used to treat intestinal strongyloidiasis and onchocerciasis, both parasitic worm infections. According to IQVIA data, Ivermectin Tablets USP, 3 mg, recorded annual sales of approximately USD 14.8 million in the United States.

The product will be manufactured at the group’s formulation manufacturing facility located in SEZ, Ahmedabad, and will be marketed and distributed in the US by Viona Pharmaceuticals Inc.

In addition, Zydus received approval for Dapsone Tablets USP in 25 mg and 100 mg strengths. Dapsone is indicated for the treatment of leprosy, including both multibacillary and paucibacillary forms, as well as dermatitis herpetiformis. The drug functions as an anti-infective and antibacterial agent, helping control skin lesions in dermatitis herpetiformis while playing a critical role in leprosy treatment.

Dapsone Tablets will be manufactured at the group’s formulation facility at SEZ-II, Ahmedabad, and distributed by Viona Pharmaceuticals Inc. The product had annual sales of USD 8.4 million in the US, based on IQVIA MAT data for December 2025.

With these latest approvals, Zydus Lifesciences continues to expand its US generics portfolio. The company now has 434 approvals and has filed 505 ANDAs since it began its filing process in FY 2003-04, reflecting its sustained focus on regulated markets and pipeline expansion.

Abbott partners Novo Nordisk India to launch Extensior for Type 2 Diabetes in India

Aman Shukla — Fri, 27 Feb 2026 10:20:59 +0000

Abbott has announced a strategic collaboration with Novo Nordisk India to commercialize Extensior® for people living with type 2 diabetes, marking a significant step toward expanding access to advanced diabetes treatment across India. The partnership combines Novo Nordisk’s scientific leadership in GLP-1 therapies with Abbott’s strong distribution network, enabling broader reach beyond regions currently served by Novo Nordisk.

Extensior® is a second brand of Ozempic, the world’s most prescribed GLP-1 receptor agonist (GLP-1 RA). Approved as an adjunct to diet and exercise for adults with type 2 diabetes, Extensior® contains semaglutide, a molecule that has demonstrated strong efficacy in improving glycaemic control and delivering additional health benefits.

Semaglutide has shown powerful HbA1c reduction, compelling weight-loss outcomes, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes. Its safety and effectiveness are backed by more than 44 clinical trials and over 10 real-world studies spanning type 2 diabetes, obesity, cardiovascular disease, liver conditions, and kidney disease. Globally, semaglutide has been on the market for nearly a decade and has accumulated more than 49 million patient-years of use across all semaglutide products, reinforcing its well-established safety profile.

The collaboration comes at a critical time for India, where diabetes continues to pose a growing public health challenge. More than 100 million individuals in the country are currently living with diabetes, and this number is projected to rise to over 150 million by 2050, reflecting a 50% increase. Factors such as rapid urbanisation, aging populations, increasing obesity, and lifestyle changes are contributing to the surge in cases.

Cardiovascular and kidney complications account for a significant portion of the long-term risks faced by people with type 2 diabetes. However, India faces a serious detection gap, with 43% of individuals with diabetes remaining undiagnosed, limiting opportunities for early treatment and risk reduction. The economic burden is also mounting, with national diabetes-related expenditure already exceeding USD 9.8 billion, or more than INR 88,000 crore.

Glenmark Pharma’s US arm to launch Sodium Phosphates Injection USP

Aman Shukla — Fri, 27 Feb 2026 03:57:18 +0000

Glenmark Pharmaceuticals Inc., the US arm of Glenmark Pharmaceuticals Ltd., has announced the upcoming launch of Sodium Phosphates Injection USP in the United States, with distribution scheduled to begin in April 2026. The injectable product will be available in three single-dose vial strengths: 15 mM P/5 mL, 45 mM P/15 mL, and 150 mM P/50 mL (3 mM P/mL).

The company stated that its Sodium Phosphates Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Sodium Phosphates Injection USP, 45 mM P/15 mL (3 mM P/mL), marketed by Hospira, Inc. under NDA 018892. The 15 mM P/5 mL and 150 mM P/50 mL (3 mM P/mL) presentations are also expected to have the same therapeutic effect as the listed drug product relied upon by the US Food and Drug Administration (FDA) as the basis for safety and effectiveness.

Glenmark clarified that the product has been approved only for the indications mentioned in its approved label and is not being marketed for all indications of the reference listed drug.

According to IQVIA National Sales Perspectives data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP market, including the brand and all available therapeutic equivalents, recorded annual sales of approximately $66.8 million in the US. The IQVIA data obtained by Glenmark reflects retail and non-retail sales across approved RLD indications.

Commenting on the development, Marc Kikuchi, President and Business Head, North America, said the upcoming launch reinforces the company’s commitment to bringing quality and affordable alternatives to patients while expanding its portfolio within the institutional channel. The launch is expected to further strengthen Glenmark’s presence in the US injectable and hospital-focused generics segment.

Nutrishifts by Preety- Science-Backed Nutrition for Sustainable, Real-Life Wellness

News Desk — Wed, 25 Feb 2026 16:44:32 +0000

Nutrishifts by Preety is a holistic health coaching brand committed to transforming lives through personalized, sustainable nutrition and lifestyle strategies. Rooted in science and guided by compassion, Nutrishifts helps individuals move beyond short-term fixes to create lasting wellness, vitality, and balance.

Founded by Preety, a certified Health Coach from the prestigious Institute for Integrative Nutrition (IIN), New York, Nutrishifts reflects her deep belief that true health is not about restriction or perfection, but about alignment—between body, mind, and lifestyle. With multiple awards recognizing her contributions to wellness and health advocacy, Preety brings both expertise and empathy to her work, making her guidance practical, relatable, and results-driven.

At Nutrishifts, health is approached holistically. Each client is treated as unique, with personalized plans that consider nutrition, daily habits, stress management, sleep, movement, and mindset. Rather than prescribing one-size-fits-all diets, Preety focuses on understanding individual needs, preferences, and challenges to design realistic strategies that fit seamlessly into everyday life. Her coaching is grounded in evidence-based nutrition while remaining flexible and culturally inclusive.

Nutrishifts is especially known for helping individuals improve energy levels, manage weight naturally, support gut and metabolic health, balance hormones, and build a healthier relationship with food. Through education, accountability, and ongoing support, clients learn how to make informed choices, break unhealthy patterns, and develop confidence in their ability to nourish themselves.

What truly sets Nutrishifts apart is its emphasis on long-term transformation. Preety believes that sustainable health comes from small, consistent shifts—habits that are easy to maintain and powerful enough to create meaningful change over time. Her coaching style is supportive yet empowering, encouraging clients to listen to their bodies, trust the process, and celebrate progress beyond the scale.

Nutrishifts by Preety is more than a health coaching practice—it is a movement toward conscious living and self-care. By helping individuals shift their habits, mindset, and relationship with food, Nutrishifts inspire a healthier, happier, and more energized future—one sustainable choice at a time.

Zydus Lifesciences to launch Semaglutide Injection in India

Aman Shukla — Wed, 25 Feb 2026 13:28:54 +0000

Zydus Lifesciences Limited, an innovation-led life sciences company with a strong international presence, is set to launch Semaglutide Injection in India under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™ following the expiry of the Semaglutide patent in the country. The Drug Controller General of India (DCGI) has already granted approval for the manufacturing and marketing of Semaglutide injection for the treatment of Type 2 Diabetes Mellitus and Obesity, paving the way for the company’s entry into this high-growth therapeutic segment.

The planned launch stands out due to Zydus’ indigenously developed drug delivery system. Unlike existing treatment options that require patients to purchase multiple single-dose pens while titrating their dosage, Zydus intends to introduce an adjustable single-pen device designed to deliver varying dose strengths from one reusable unit. This approach is expected to simplify the treatment process, enhance patient convenience and improve long-term adherence to therapy.

The reusable pen technology will be capable of delivering all strengths approved for the treatment of Type 2 Diabetes Mellitus and Obesity. With exclusive rights to this novel device, Zydus aims to address cost concerns often associated with GLP-1 based therapies, potentially making treatment more affordable and accessible for patients across India.

The introduction of Semaglutide by Zydus comes at a time when India continues to face a growing burden of diabetes and obesity. According to the International Diabetes Federation, India has approximately 8.9 crore adults living with diabetes, accounting for 10.5% of the total adult population. At the same time, obesity rates have risen sharply in recent years, with significant increases observed among both women and men, reflecting an expanding public health challenge.

GLP-1 based therapies such as Semaglutide have gained prominence globally for their role in managing blood glucose levels and supporting weight reduction. With regulatory approval already in place and an innovative drug delivery mechanism ready for rollout, Zydus Lifesciences is positioning itself to strengthen its footprint in India’s diabetes and obesity treatment market.

Lupin receives USFDA approval for Brivaracetam Oral Solution, launches in US market

Aman Shukla — Tue, 24 Feb 2026 13:47:59 +0000

Lupin Limited has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL, marking another addition to its growing U.S. generics portfolio. Following the approval, the company has initiated the launch of the product in the United States.

The approved product is bioequivalent to Briviact® Oral Solution 10 mg/mL of UCB, Inc. and is indicated for the treatment of partial-onset seizures in patients aged one month and older. Brivaracetam is commonly prescribed as part of epilepsy management therapy and falls under the central nervous system (CNS) treatment segment, an area where Lupin already maintains a strong presence.

According to IQVIA MAT data for December 2025, the reference listed drug (RLD) Briviact Oral Solution recorded estimated annual sales of USD 135 million in the United States. The approval positions Lupin to tap into this established market opportunity with a therapeutically equivalent generic alternative.

The launch further strengthens Lupin’s footprint in the U.S., one of its key focus markets. The company continues to expand its pipeline of complex generics and specialty products, with a focus on delivering cost-effective treatment options across multiple therapy areas.

Headquartered in Mumbai, Lupin operates in over 100 markets worldwide. The company manufactures branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It has 15 manufacturing facilities and seven research centres globally, supported by a workforce of more than 24,000 professionals. Lupin maintains a strong presence in India and the U.S. across therapy segments including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.

Caplin Point subsidiary secures USFDA approval for Sodium Phosphates Injection

Aman Shukla — Tue, 24 Feb 2026 06:51:18 +0000

Caplin Steriles Limited, a wholly owned subsidiary of Caplin Point Laboratories Limited (BSE: 524742 | NSE: CAPLIPOINT), has secured final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Sodium Phosphates Injection USP in multiple strengths.

The approval covers 15mM P/5mL, 45mM P/15mL and 150mM P/50mL (3mM P/mL) single-dose vials. The product is a generic therapeutic equivalent of the Reference Listed Drug (RLD) marketed by Hospira Inc. in the United States under NDA 018892.

Sodium Phosphates Injection is indicated as a source of phosphorus and is administered as an additive to large volume intravenous fluids. It is primarily used to prevent or treat hypophosphatemia in patients who have restricted or no oral intake. The drug is also utilised in preparing customised parenteral nutrition formulations when standard electrolyte or nutrient solutions do not adequately meet patient needs. The product is widely used in hospital and critical care settings, where maintaining electrolyte balance is crucial.

According to IQVIA (IMS Health) data, the approved strengths of Sodium Phosphates Injection USP recorded total US sales of approximately $67 million for the 12-month period ending December 2025. The approval opens up a sizeable opportunity for Caplin Steriles in the US hospital injectable segment.

Eris Lifesciences partners with Natco Pharma to launch Semaglutide in India

Aman Shukla — Tue, 24 Feb 2026 06:46:59 +0000

Eris Lifesciences Limited has entered into a strategic partnership with Natco Pharma Limited for the commercialisation of semaglutide in India, strengthening its position in the rapidly expanding diabetes and metabolic care market. The move reinforces Eris’ commitment to deepening its leadership in chronic and specialty therapies, particularly in diabetology.

Semaglutide, a GLP-1 receptor agonist, has emerged globally as a breakthrough therapy in the management of Type 2 diabetes and chronic weight management. Backed by strong clinical outcomes, the molecule has demonstrated significant benefits in glycemic control along with meaningful weight reduction. With India witnessing a sharp rise in diabetes cases and increasing awareness around obesity-related complications, GLP-1 therapies are seen as a high-growth opportunity within the broader metabolic segment.

In a key regulatory development, Natco Pharma has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market. Following this approval, the product launch is expected in March 2026. The approval marks an important milestone, paving the way for broader access to advanced diabetes treatment options in the country.

Eris Lifesciences has built a strong and scalable presence in diabetology over the years, supported by a wide specialist reach and consistent engagement with endocrinologists, diabetologists and physicians across India. The addition of semaglutide is expected to further strengthen the company’s advanced diabetes portfolio and enhance its participation in next-generation metabolic therapies.

Indoco Remedies receives USFDA final approval for Brivaracetam Oral Solution 10 mg/mL

Aman Shukla — Tue, 24 Feb 2026 06:20:48 +0000

Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution, 10 mg/mL, marking another key milestone in its regulated markets portfolio.

The approval allows the company to market a generic version of Briviact 10 mg/mL, originally developed by UCB, Inc.. The product has been confirmed to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), ensuring the same safety, quality, and efficacy standards.

What Is Brivaracetam Oral Solution Used For?

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (AED), also known as an anticonvulsant. It is used in the treatment of partial-onset seizures in patients aged one month and older. Partial-onset seizures, also referred to as focal seizures, begin in one area of the brain and are among the most common types of seizures.

The approval strengthens Indoco’s presence in the central nervous system (CNS) segment in the United States, a highly regulated and competitive pharmaceutical market.

Manufacturing Details

The approved product will be manufactured at Indoco Remedies’ state-of-the-art facility located at L-14, Verna Industrial Area, Verna, Goa, India. The facility complies with global regulatory standards, supporting the company’s expanding footprint in regulated markets such as the US.

Nishant Singhal: Visionary Entrepreneur and CEO Driving Healthians’ Mission to Revolutionize At-Home Diagnostics in India

News Desk — Thu, 19 Feb 2026 04:58:09 +0000

Nishant Singhal is a dynamic entrepreneur, investor, and business leader with over two decades of experience across finance, consulting, healthcare, real estate, and venture capital. Today, he serves as the Board Member & CEO at Healthians, India’s leading at-home diagnostics company — a role that reflects his deep passion for building impactful businesses that touch people’s lives.

Nishant’s journey with Healthians began more than eight years ago when he made an angel investment through YouWeCan Ventures, a startup fund he co-founded with cricketer Yuvraj Singh. What started as an investor relationship evolved into a hands-on leadership role. As COO from May 2020 to July 2023, he helped steer the company through an incredible growth phase — scaling monthly revenues from ₹2 crore to ₹25 crore in just 18 months and raising over $100 million from reputed investors like Westbridge Capital, Beenext, and Evolvence Fund.

With a strong foundation as a Chartered Accountant and All-India Rank Holder, Nishant graduated from Shri Ram College of Commerce (SRCC) — one of India’s most prestigious institutions. He began his career at PwC, where he spent over 11 years advising top corporations in telecom, media, and e-commerce. His work took him across global markets, from Paris and Birmingham to Malaysia and Germany. He was instrumental in leading high-profile IPOs for companies like NDTV, TV Today, and Naukri.com, and worked with major clients including Bharti Group, India Today Group, and Delhi Metro.

In 2011, Nishant took the leap into entrepreneurship and co-founded Investors Clinic, which grew to become one of India’s largest real estate services companies. Not one to stay within a single sector, he went on to co-build YouWeCan Ventures, investing in over 15 startups across healthcare, aviation, hospitality, and sports education — and delivering outstanding returns, with some exits yielding over 100X.

What sets Nishant apart is his unique blend of analytical thinking and instinctive leadership. He’s a strong believer in listening first, understanding diverse perspectives, and then making clear, confident decisions. He’s known for his speed of execution, willingness to take calculated risks, and ability to rally teams around a shared vision.

Whether he’s scaling a healthcare brand or mentoring startup founders, Nishant brings authenticity, clarity, and a deep sense of purpose to everything he does. He thrives on solving complex challenges, building high-impact ventures, and helping others succeed along the way.

Above all, Nishant is passionate about building businesses that matter — ones that are not just financially successful, but meaningful in the lives they touch.

Zydus Lifesciences lunches Anyra, India’s first indigenously developed Aflibercept 2 mg biosimilar for retinal diseases

Aman Shukla — Thu, 19 Feb 2026 04:21:14 +0000

Zydus Lifesciences Ltd., an innovation-led global life sciences company, has announced the launch of Anyra™, India’s first indigenously developed biosimilar of Aflibercept 2 mg. The company has also signed an agreement with Regeneron Pharmaceuticals, Inc. and Bayer in connection with the product.

Anyra™ is indicated for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion, including Branch RVO and Central RVO, visual impairment due to Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization (mCNV). These chronic retinal conditions require timely anti-VEGF therapy to prevent irreversible vision loss and long-term complications.

India is home to more than 100 million people living with diabetes, making it one of the largest diabetic populations in the world. Diabetic Retinopathy affects an estimated 7–8 million individuals, many of whom progress to vision-threatening stages such as DME. Wet AMD impacts nearly 1.5–2 million elderly patients, while Retinal Vein Occlusions affect more than 2 million individuals. Collectively, these conditions represent a large patient pool in need of sustained retinal therapy.

As chronic retinal diseases typically require repeated intravitreal injections over extended periods, affordability and continuity of care remain key challenges. Improved access to biosimilar anti-VEGF therapies can significantly enhance treatment adherence, reduce preventable blindness, and lower the long-term disease burden on both patients and healthcare systems.

Commenting on the launch, Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Ltd., stated that the introduction of Anyra™ marks a significant step toward expanding access to advanced biologics in India. The company continues to focus on delivering high-quality, affordable therapies through indigenous research, scientific innovation, and patient-centric healthcare solutions.

Zydus currently holds India’s largest biosimilar portfolio, with more than 13 biosimilars and complex biologic molecules developed and manufactured entirely in the country. The company has established end-to-end capabilities across biologics development, from cell line research and process engineering to clinical trials, manufacturing, and regulatory approvals. The launch of Anyra™ further strengthens its position in the ophthalmology and biosimilars segment while reinforcing its commitment to advancing retinal care in India.

Zydus Lifesciences launches India’s first affordable OPEP device PEPAIR

Aman Shukla — Tue, 17 Feb 2026 04:54:45 +0000

Zydus Lifesciences Limited, an innovation-led global life sciences company, has announced the launch of PEPAIR™, India’s first affordable Oscillating Positive Expiratory Pressure (OPEP) device featuring a unique 3-resistance system. The drug-free, handheld respiratory device is designed to help patients suffering from chronic respiratory conditions such as COPD, asthma, and bronchiectasis by supporting effective mucus clearance and improving breathing.

The company has introduced PEPAIR™ at a patient-friendly price of Rs. 990 per unit, aiming to bridge the accessibility gap in airway clearance therapy across India. The device is being launched in partnership with AeroDel Technology Innovations Pvt. Ltd., a medical device company focused on inhalation drug delivery and pulmonary rehabilitation solutions.

What is PEPAIR™ and How Does It Work?

PEPAIR™ is an innovative OPEP device that creates positive pressure and oscillations during exhalation. These vibrations help loosen mucus trapped in the airways, open breathing passages, and promote better mucus clearance. The device is particularly beneficial for patients experiencing chronic mucus hypersecretion, a common complication in respiratory disorders.

OPEP therapy is clinically recommended for airway clearance. However, affordability constraints have historically limited access for a large section of patients. With PEPAIR™, Zydus aims to make daily respiratory care more accessible and practical for millions of Indians.

Addressing India’s Growing Respiratory Health Burden

More than 90 lakh patients in India suffer from chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and bronchiectasis. Rising air pollution, climate-driven allergen changes, rapid urbanisation, and delayed diagnosis of lung diseases have significantly contributed to the surge in respiratory ailments across the country.

By offering a non-pharmacological, drug-free solution, PEPAIR™ provides an everyday airway clearance option that complements existing inhalation and oral therapies.

Ovulation Calculator: How to Find Your Most Fertile Days for Pregnancy

News Desk — Sat, 14 Feb 2026 18:25:42 +0000

Planning a pregnancy can feel both exciting and overwhelming for a couple, especially first-time parents. Certain questions can also arise quickly, like When is the right time? Am I fertile today? Why does timing matter so much? While conception depends on multiple biological factors, one element plays a decisive role: ovulation.

Understanding when ovulation occurs can dramatically improve the chances of pregnancy, and this is where an Ovulation Calculator becomes a valuable companion.

Rather than guessing or relying solely on physical signs, modern tools provide clarity by translating menstrual data into fertile windows. When used correctly, they simplify one of the most complex aspects of conception planning.

What Ovulation Really Means in the Fertility Journey?

Ovulation is the process by which an ovary releases a mature egg. Once released, that egg survives for about 12 to 24 hours. This overlap creates a short fertile window each cycle when pregnancy is most likely to occur.

Because this window is limited, timing becomes crucial. Missing it by even a couple of days can significantly reduce the chances of conception in that cycle.

Let’s Understand: Ovulation Calculator and Its Work?

An Ovulation Calculator estimates fertile days based on cycle length and the first day of the last menstrual period. Most ovulation events occur roughly 12–14 days before the next period begins, regardless of overall cycle length.

After a pattern is studied and analysed, the calculator predicts the days when ovulation is most likely to happen. It then highlights the fertile window, which typically is five days before ovulation and the day of ovulation itself. This provides couples a clear timeframe for planning intimacy.

Know Your Fertile Window

Trying to conceive without understanding ovulation can often lead to frustration. Many couples assume pregnancy can happen anytime during the month, which is not accurate in biological terms.

Focusing efforts during the fertile window increases success rates without adding stress or unnecessary medical intervention. It also helps couples avoid burnout by replacing constant attempts with strategic timing.

Signs That Support Ovulation Predictions

While calculators provide estimates, combining them with physical observations improves accuracy. Changes in cervical mucus are one such indicator. Around ovulation, mucus often becomes clear, stretchy, and slippery. This is similar to egg whites which create an ideal environment for sperm.

Some women experience mild pelvic discomfort known as mittelschmerz. Others notice increased libido or heightened senses. Tracking these patterns alongside calculated dates offers a fuller picture of fertility rhythms.

Let’s Understand: Irregular Cycles and Ovulation Tracking

Not everyone has predictable cycles. Stress, weight changes, hormonal conditions, or lifestyle disruptions can shift ovulation timing. In such cases, calculators still offer guidance, but additional tracking methods such as basal body temperature or ovulation predictor kits may help refine estimates.

Irregular patterns do not automatically mean infertility. But they do require closer observation and patience for a better understanding of the issue.

How Long Should You Try Before Seeking Help?

For most healthy couples under 35, trying for up to a year is considered normal before consulting a specialist. For those over 35, medical advice is often recommended after six months.

Using an ovulation tool during this period ensures attempts are well-timed. If conception doesn’t occur despite accurate tracking, a healthcare provider can explore underlying causes and suggest next steps.

Why is Emotional Balance Important While Tracking Fertility?

Fertility tracking can sometimes feel mechanical, reducing intimacy to dates on a calendar. This might also feel like a technical process to some couples. Thus, it’s important to maintain emotional connection and avoid letting numbers dominate the relationship.

Using an Ovulation Calculator should support and not control the journey. Flexibility, communication, and emotional care are just as important as biological timing.

Let’s Understand: Pregnancy Planning and Financial Preparedness

Once a couple firmly decides to have a baby, thinking ahead about healthcare coverage makes sense. Antenatal visits, diagnostic tests, delivery costs, and postnatal care all involve expenses.

Exploring maternity insurance policies early allows couples to understand waiting periods, coverage limits, and hospital networks. Many plans require enrollment well before conception, making early research essential.

Combining fertility awareness with financial planning creates a more secure foundation for parenthood.

When are Ovulation Calculators Most Effective?

These tools are most effective for women with relatively consistent menstrual cycles. Over time, entering accurate data improves prediction reliability. Even with minor variations, calculators offer a structured starting point.

They are not diagnostic tools but planning aids. Medical evaluation remains important if conception challenges persist.

How Do Lifestyle Choices Support Fertility?

Ovulation responds positively to balanced nutrition, adequate sleep, moderate exercise, and stress management. Extreme dieting or overtraining may disrupt hormonal balance.

One should avoid smoking, limit alcohol, and manage chronic conditions to support reproductive health.

Conclusion

Pregnancy planning is a combination of science, patience, and emotional readiness for couples. An Ovulation Calculator removes guesswork, replacing uncertainty with clarity. By identifying fertile days, it empowers couples to align timing with biology rather than chance.

When a couple blends both physical and financial strengths, including reviewing maternity insurance policies, the path toward parenthood feels more confident and less overwhelming.

NATCO Pharma gets CDSCO approval for Generic Semaglutide Injection, launch set for March 2026

Aman Shukla — Sat, 14 Feb 2026 04:37:33 +0000

NATCO Pharma Limited (BSE: 524816 | NSE: NATCOPHARM) has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market generic Semaglutide Injection in India. The company has announced that the product will be launched in the domestic market in March 2026, marking its entry into one of the fastest-growing segments in diabetes treatment.

Semaglutide is indicated for the treatment of adults with insufficiently controlled Type 2 diabetes mellitus and is prescribed as an adjunct to diet and exercise. With diabetes cases continuing to rise across India, the approval is expected to improve accessibility to advanced GLP-1-based therapies at a potentially more affordable cost.

Headquartered in Hyderabad, NATCO Pharma Limited develops, manufactures and distributes generic and branded pharmaceuticals, specialty medicines, active pharmaceutical ingredients and crop protection products. The company is known for its strong research-driven approach and has established itself as a leading oncology player in the domestic targeted therapies market. It also focuses on limited-competition molecules in the United States, strengthening its presence in regulated markets.

NATCO operates nine manufacturing facilities and two R&D centers in India. Its plants are approved by leading regulatory authorities including the U.S. FDA, Brazil’s ANVISA, Health Canada and the WHO. The company supplies products to more than 50 global markets, underlining its strong international footprint.

Alembic Pharmaceuticals gets USFDA final approval for Carbidopa, Levodopa and Entacapone tablets

Aman Shukla — Fri, 06 Feb 2026 06:04:15 +0000

Alembic Pharmaceuticals Limited has announced a major regulatory milestone after securing final approval from the US Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Carbidopa, Levodopa and Entacapone Tablets. The approval covers multiple strengths, including 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg.

The approved formulation is therapeutically equivalent to the reference listed drug Stalevo Tablets, originally developed by Orion Corporation. These tablets are widely prescribed for the treatment of Parkinson’s disease, a chronic and progressive neurological disorder that affects movement and coordination. The approval allows Alembic to market a cost-effective generic version in the US market, subject to standard regulatory conditions.

This development further strengthens Alembic’s presence in the highly regulated US generics space. With this latest clearance, the company’s cumulative USFDA approvals have reached 234 ANDAs, comprising 214 final approvals and 20 tentative approvals. The expanding approval base reflects Alembic’s consistent focus on complex and differentiated products across therapeutic segments.

Gland Pharma gets USFDA nod for Zoledronic Acid Injection for US market

Aman Shukla — Fri, 06 Feb 2026 05:47:21 +0000

Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL) in single-dose bags, marking another regulatory milestone for the company’s US generics portfolio.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL) of InfoRLife. Zoledronic Acid Injection is widely used in oncology care and is indicated for the treatment of hypercalcemia of malignancy, multiple myeloma, and bone metastases arising from solid tumors. These indications make the product clinically significant in managing skeletal-related complications in cancer patients.

This USFDA approval strengthens Gland Pharma’s presence in the high-value injectable generics segment, where regulatory entry barriers are relatively high and competition is limited compared to oral solids. The product will be marketed in a ready-to-use single-dose bag format, a presentation that is often preferred in hospital settings due to ease of administration and reduced preparation time.

According to IQVIA, Zoledronic Acid Injection recorded US sales of approximately USD 6.7 million for the twelve months ended November 2025. While the market size is modest, such niche injectable products typically offer stable demand and attractive margins, supporting long-term revenue visibility for manufacturers with strong compliance capabilities.

Lupin launches Topiramate Extended-Release Capsules in the US after FDA approval

Aman Shukla — Wed, 04 Feb 2026 15:23:50 +0000

Lupin Limited has announced the launch of Topiramate Extended-Release Capsules in the United States, marking another key addition to its US generics portfolio. The launch follows approval of the company’s Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration.

The newly launched product is available in strengths of 25 mg, 50 mg, 100 mg, and 200 mg. Lupin stated that its Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug Trokendi XR®, which is marketed by Supernus Pharmaceuticals, Inc..

Topiramate Extended-Release Capsules are indicated for a wide range of neurological conditions. These include use as initial monotherapy for the treatment of partial-onset seizures or primary generalized tonic-clonic seizures in patients aged 6 years and above. The drug is also approved as adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in the same age group. In addition, the medication is indicated for the preventive treatment of migraine in patients aged 12 years and older.

According to market data from IQVIA, Topiramate Extended-Release Capsules have an estimated annual sales potential of USD 164 million in the US, based on MAT December 2025 figures. This highlights the commercial significance of the launch and underlines the opportunity for Lupin to strengthen its presence in the US central nervous system (CNS) therapy segment.

Zydus Lifesciences receives USFDA tentative approval for Dapagliflozin Tablets

Aman Shukla — Wed, 04 Feb 2026 09:13:29 +0000

Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has received tentative approval from the United States Food and Drug Administration (USFDA) for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The reference listed drug for this approval is Farxiga® Tablets, a widely prescribed therapy in the United States for the management of type 2 diabetes.

Dapagliflozin belongs to the SGLT2 inhibitor class of medicines and is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. The drug has also gained strong physician acceptance due to its additional benefits in diabetes-related cardiovascular and renal outcomes, making it a key product in the US anti-diabetic market.

The approved Dapagliflozin tablets will be manufactured at Zydus’ formulation manufacturing facility located at SEZ, Ahmedabad, reinforcing the group’s strong manufacturing and regulatory compliance capabilities for regulated markets such as the United States.

From a market opportunity perspective, Dapagliflozin is a high-value product. As per IQVIA MAT December 2025, the drug recorded annual sales of USD 10,486.9 million in the United States, highlighting the significant revenue potential once final approval and commercialisation are achieved.

With this latest development, Zydus continues to scale its US generics business. The group now has 430 USFDA approvals and has filed a cumulative 505 ANDAs since the commencement of its ANDA filing process in FY 2003–04, underscoring its long-term focus on the US generics and specialty pharmaceuticals market.

Sun Pharma receives FDA Rare Pediatric Disease Priority Review Voucher for Sezaby

Aman Shukla — Tue, 03 Feb 2026 03:00:20 +0000

Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the United States Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Priority Review Voucher (PRV) linked to the approval of Sezaby®. The development marks a meaningful regulatory milestone for SPARC and strengthens the company’s strategic position in advancing therapies for rare pediatric conditions.

The PRV programme is designed to incentivise innovation in treatments for rare pediatric diseases. Such vouchers are awarded by the United States Food and Drug Administration and can be traded or redeemed to obtain a priority review for a future, separate drug application. Priority review status shortens the FDA’s standard review timeline, potentially enabling faster regulatory decisions for subsequent products in a company’s pipeline.

Sezaby® receiving approval and the associated PRV highlights the therapeutic relevance of the drug in addressing unmet medical needs in pediatric care. The voucher provides SPARC with additional flexibility, as it can either be used internally to accelerate the review of another candidate or monetised through a sale to other pharmaceutical companies, a route often taken to fund further research and development.

Lupin collaborates with TB Alliance to advance new treatment for Tuberculosis and other mycobacterial diseases

Aman Shukla — Mon, 02 Feb 2026 04:44:05 +0000

Lupin Limited has announced a strategic collaboration with TB Alliance to support the clinical development and future commercialization of the investigational drug Telacebec, formerly known as Q203. The drug is being developed to treat multiple mycobacterial diseases, including tuberculosis (TB), leprosy, and Buruli ulcer.

Under the terms of the agreement, TB Alliance will continue to lead the clinical development of Telacebec, while Lupin will contribute its expertise in large-scale manufacturing, regulatory affairs, and global supply chain management. The partnership aims to ensure broader and more equitable global access to the treatment once it progresses through development.

The collaboration focuses on addressing diseases that continue to pose significant public health challenges, particularly in low- and middle-income countries. Tuberculosis remains one of the leading infectious causes of death worldwide, while leprosy and Buruli ulcer are considered neglected tropical diseases with limited treatment options.

Commenting on the development, Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU at Lupin, said the partnership reflects the company’s long-standing commitment to addressing unmet medical needs. He noted that combining Lupin’s manufacturing and distribution capabilities with TB Alliance’s drug development expertise could help deliver timely treatment options to patients affected by these diseases.

Mel Spigelman, MD, President and CEO of TB Alliance, said Telacebec has the potential to significantly improve treatment outcomes for diseases that have historically received limited research attention. He added that working with Lupin would help advance the compound responsibly while strengthening access capabilities across global markets.